

# Therapeutic efficacy of the small molecule GS-5734 agai

Nature

531, 381-385

DOI: [10.1038/nature17180](https://doi.org/10.1038/nature17180)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications. <i>Viruses</i> , 2016, 8, 206.	3.3	40
3	Therapeutic post-infection options for Ebola virus treatment set to broaden. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 307-307.	46.4	0
4	Maladie À virus Ebola: actualit�s th�rapeutiques. <i>Journal Des Anti-infectieux</i> , 2016, 18, 117-125.	0.1	2
5	The Liberia Men's Health Screening Program for Ebola virus: win-win-win for survivor, scientist, and public health. <i>The Lancet Global Health</i> , 2016, 4, e672-e673.	6.3	1
6	A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. <i>New England Journal of Medicine</i> , 2016, 375, 1448-1456.	27.0	429
7	Efficacy of Vesicular Stomatitis Virus�Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona. <i>Journal of Infectious Diseases</i> , 2016, 214, S360-S366.	4.0	62
8	Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga. <i>Journal of Infectious Diseases</i> , 2016, 214, S355-S359.	4.0	9
9	New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase. <i>Antiviral Research</i> , 2016, 134, 63-76.	4.1	51
10	Bifunctional aryloxyphosphoramidate prodrugs of 2�C-Me-uridine: synthesis and anti-HCV activity. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 8743-8757.	2.8	4
11	Molecular mechanisms of Ebola pathogenesis. <i>Journal of Leukocyte Biology</i> , 2016, 100, 889-904.	3.3	31
12	Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10400-10410.	6.4	76
13	Antiviral therapeutics for the treatment of Ebola virus infection. <i>Current Opinion in Pharmacology</i> , 2016, 30, 138-143.	3.5	17
14	Ebola virus disease and the eye. <i>Current Opinion in Ophthalmology</i> , 2016, 27, 538-544.	2.9	16
15	The ProTides Boom. <i>ChemMedChem</i> , 2016, 11, 1114-1116.	3.2	36
16	Experimental Therapies for Ebola Virus Disease: What Have We Learned?. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw496.	4.0	23
17	First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw493.	4.0	104
18	Will There Be a Cure for Ebola?. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 329-348.	9.4	40
19	Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1- <i>f</i> ] [triazin-4-amino] Adenine <i>C</i> -Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1648-1661.	6.4	547

#	ARTICLE	IF	CITATIONS
20	Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds. <i>European Journal of Medicinal Chemistry</i> , 2017, 129, 53-71.	5.5	22
21	Filovirus proteins for antiviral drug discovery: Structure/function bases of the replication cycle. <i>Antiviral Research</i> , 2017, 141, 48-61.	4.1	29
22	The one-carbon metabolism pathway highlights therapeutic targets for gastrointestinal cancer (Review). <i>International Journal of Oncology</i> , 2017, 50, 1057-1063.	3.3	41
23	Emerging sexually transmitted viral infections: 1. Review of Ebola virus disease. <i>International Journal of STD and AIDS</i> , 2017, 28, 1352-1359.	1.1	5
24	Flex-nucleoside analogues – Novel therapeutics against filoviruses. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2800-2802.	2.2	28
25	How to treat Ebola virus infections? A lesson from the field. <i>Current Opinion in Virology</i> , 2017, 24, 9-15.	5.4	15
27	Respiratory syncytial virus: prospects for new and emerging therapeutics. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 609-615.	2.5	58
28	Interferon- $\beta$ and Interferon- $\gamma$ Are Weak Inhibitors of Ebola Virus in Cell-Based Assays. <i>Journal of Infectious Diseases</i> , 2017, 215, 1416-1420.	4.0	9
29	Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus. <i>Topics in Current Chemistry</i> , 2017, 375, 40.	5.8	18
30	GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. <i>Scientific Reports</i> , 2017, 7, 43395.	3.3	373
31	Nidovirus RNA polymerases: Complex enzymes handling exceptional RNA genomes. <i>Virus Research</i> , 2017, 234, 58-73.	2.2	96
32	The Pathogenesis of Ebola Virus Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 387-418.	22.4	266
33	Control of $\beta$ Anomer Formation by a 2,5 Bridge: Toward Nucleoside Derivatives Locked in the South Conformation. <i>Journal of Organic Chemistry</i> , 2017, 82, 11337-11347.	3.2	3
34	Discovering Drugs for the Treatment of Ebola Virus. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 299-317.	1.9	51
35	Identification and pathological characterization of persistent asymptomatic Ebola virus infection in rhesus monkeys. <i>Nature Microbiology</i> , 2017, 2, 17113.	13.3	104
36	Pyrrolo[2,1-f][1,2,4]triazines: From C-nucleosides to kinases and back again, the remarkable journey of a versatile nitrogen heterocycle. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4238-4246.	2.2	19
37	High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona. <i>Scientific Reports</i> , 2017, 7, 5886.	3.3	20
38	Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. <i>Drugs</i> , 2017, 77, 1935-1966.	10.9	156

#	ARTICLE	IF	CITATIONS
39	Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. <i>Scientific Reports</i> , 2017, 7, 4099.	3.3	11
40	Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	1,279
41	Ebola: Anatomy of an Epidemic. <i>Annual Review of Medicine</i> , 2017, 68, 359-370.	12.2	44
42	Viral Hemorrhagic Fevers. , 2017, , 1110-1118.e2.		0
43	Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 155-169.	9.4	23
44	The early clinical development of Ebola virus treatments. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1-4.	4.1	3
45	Marburg- and Ebolaviruses. <i>Current Topics in Microbiology and Immunology</i> , 2017, , .	1.1	4
46	Therapeutics Against Filovirus Infection. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 263-290.	1.1	3
47	New Strategy Treating Hepatitis B Virus (HBV) Infection: A Review of HBV Infection Biology. , 0, , .		1
48	Clinical Laboratory Values as Early Indicators of Ebola Virus Infection in Nonhuman Primates. <i>Emerging Infectious Diseases</i> , 2017, 23, 1316-1324.	4.3	13
49	Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: Polymerase activity and mechanisms of action of nucleotide analogs. <i>PLoS ONE</i> , 2017, 12, e0185998.	2.5	10
50	The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005540.	3.0	97
51	Characterization of the catalytic center of the Ebola virus L polymerase. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005996.	3.0	19
53	ZMapp. , 2017, , 49-62.		1
54	Antiviral Drugs for Acute Infections. , 2017, , 665-681.		0
55	Recombinant RNA-Dependent RNA Polymerase Complex of Ebola Virus. <i>Scientific Reports</i> , 2018, 8, 3970.	3.3	45
56	Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. <i>MBio</i> , 2018, 9, .	4.1	1,142
57	Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3582-3594.	6.4	32

#	ARTICLE	IF	CITATIONS
58	Post-exposure treatments for Ebola and Marburg virus infections. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 413-434.	46.4	104
59	Synthesis of a C-Nucleoside Phosphonate by Base-Promoted Epimerization. <i>Organic Letters</i> , 2018, 20, 1203-1206.	4.6	3
60	Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model. <i>Antiviral Research</i> , 2018, 151, 39-49.	4.1	23
61	Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E162-E171.	7.1	331
62	Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus. <i>Antiviral Research</i> , 2018, 151, 50-54.	4.1	31
63	Enhancing the antiviral potency of ER Î±-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. <i>Antiviral Research</i> , 2018, 150, 112-122.	4.1	26
64	A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication. <i>Antiviral Research</i> , 2018, 150, 193-201.	4.1	32
65	The expanding role of prodrugs in contemporary drug design and development. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 559-587.	46.4	478
66	Susceptibility of paramyxoviruses and filoviruses to inhibition by 2â€²-monofluoro- and 2â€²-difluoro-4â€²-azidocytidine analogs. <i>Antiviral Research</i> , 2018, 153, 101-113.	4.1	15
67	Nucleosides for the treatment of respiratory RNA virus infections. <i>Antiviral Chemistry and Chemotherapy</i> , 2018, 26, 204020661876448.	0.6	113
68	Ribavirin Had Demonstrable Effects on the Crimean-Congo Hemorrhagic Fever Virus (CCHFV) Population and Load in a Patient With CCHF Infection. <i>Journal of Infectious Diseases</i> , 2018, 217, 1952-1956.	4.0	20
69	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. <i>Microbiology Spectrum</i> , 2018, 6, .	3.0	6
70	Nonhuman primate models of human viral infections. <i>Nature Reviews Immunology</i> , 2018, 18, 390-404.	22.7	151
71	Current landscape and future prospects of antiviral drugs derived from microbial products. <i>Journal of Antibiotics</i> , 2018, 71, 45-52.	2.0	23
72	Retro-2 and its dihydroquinazolinone derivatives inhibit filovirus infection. <i>Antiviral Research</i> , 2018, 149, 154-163.	4.1	31
73	Treatment-focused Ebola trials, supportive care and future of filovirus care. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 67-76.	4.4	9
74	Ebola virus disease: an update on post-exposure prophylaxis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e183-e192.	9.1	112
75	Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	51

#	ARTICLE	IF	CITATIONS
76	Synthesis and Biological Evaluation of Pyrrolo[2,1- <i>f</i> ][1,2,4]triazine <i>C</i> -Nucleosides with a Ribose, 2-Deoxyribose, and 2,3-Dideoxyribose Sugar Moiety. <i>ChemMedChem</i> , 2018, 13, 97-104.	3.2	17
77	The ProTide Prodrug Technology: From the Concept to the Clinic. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2211-2226.	6.4	203
78	Clinical Laboratory Values in Human Ebola Virus Disease Support the Relevance of the Intramuscular Ebola-Kikwit Rhesus Model. <i>Clinical Infectious Diseases</i> , 2018, 66, 1479-1480.	5.8	4
79	Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens. <i>Current Drug Metabolism</i> , 2018, 18, 942-970.	1.2	8
80	Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus. <i>Viruses</i> , 2018, 10, 678.	3.3	24
81	Persistence and Sexual Transmission of Filoviruses. <i>Viruses</i> , 2018, 10, 683.	3.3	62
82	Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. <i>Nature Communications</i> , 2018, 9, 4013.	12.8	54
83	Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice. <i>Mammalian Genome</i> , 2018, 29, 367-383.	2.2	17
84	Phenotypic Prioritization of Diphyllin Derivatives That Block Filoviral Cell Entry by Vacuolar (H <sup>+</sup> )-ATPase Inhibition. <i>ChemMedChem</i> , 2018, 13, 2664-2676.	3.2	14
85	Sofosbuvir: A Potential Treatment for Ebola. <i>Frontiers in Pharmacology</i> , 2018, 9, 1139.	3.5	1
86	Antiviral Agents Against Ebola Virus Infection: Repositioning Old Drugs and Finding Novel Small Molecules. <i>Annual Reports in Medicinal Chemistry</i> , 2018, 51, 135-173.	0.9	12
87	Synthesis of a 3-Deoxy- <i>C</i> -Nucleoside Phosphonate Bearing 9-Deazaadenine as Base Moiety. <i>European Journal of Organic Chemistry</i> , 2018, 2018, 6657-6664.	2.4	1
88	Symmetrical Diamidates as a Class of Phosphate Prodrugs to Deliver the 5-Monophosphate Forms of Anticancer Nucleoside Analogues. <i>ChemMedChem</i> , 2018, 13, 2305-2316.	3.2	6
89	Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond. <i>Antiviral Research</i> , 2018, 155, 76-88.	4.1	154
90	The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. <i>Veterinary Microbiology</i> , 2018, 219, 226-233.	1.9	127
91	Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. <i>Antiviral Chemistry and Chemotherapy</i> , 2018, 26, 204020661876129.	0.6	113
92	Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. <i>Antiviral Chemistry and Chemotherapy</i> , 2018, 26, 204020661877524.	0.6	84
93	Challenges and recent progress in drug discovery for tropical diseases. <i>Nature</i> , 2018, 559, 498-506.	27.8	164

#	ARTICLE	IF	CITATIONS
94	Postexposure Protective Efficacy of T-705 (Favipiravir) Against Sudan Virus Infection in Guinea Pigs. <i>Journal of Infectious Diseases</i> , 2018, 218, S649-S657.	4.0	9
95	The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2018, 218, S690-S697.	4.0	8
96	Drug Repurposing for Viral Infectious Diseases: How Far Are We?. <i>Trends in Microbiology</i> , 2018, 26, 865-876.	7.7	196
97	Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. <i>Frontiers in Immunology</i> , 2018, 9, 1803.	4.8	65
98	Recent advances in synthetic approaches for medicinal chemistry of C-nucleosides. <i>Beilstein Journal of Organic Chemistry</i> , 2018, 14, 772-785.	2.2	46
100	Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase. <i>PLoS Pathogens</i> , 2018, 14, e1006889.	4.7	100
101	New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. <i>Chemistry - an Asian Journal</i> , 2019, 14, 3962-3968.	3.3	166
102	Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007595.	3.0	38
103	Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1023-1032.	9.1	48
104	Therapeutic strategies to target the Ebola virus life cycle. <i>Nature Reviews Microbiology</i> , 2019, 17, 593-606.	28.6	110
105	Small-Molecule Antiviral $\hat{2}$ - <i>N</i> <sup>4</sup> -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. <i>Journal of Virology</i> , 2019, 93, .	3.4	252
106	Synthesis of $\hat{1}$ -Cyano and $\hat{1}$ -Sulfonyl Cyclic Ethers via Intramolecular Reactions of Peroxides with Sulfone- and Nitrile-Stabilized Carbanions. <i>Journal of Organic Chemistry</i> , 2019, 84, 14611-14626.	3.2	18
107	Measles Encephalitis: Towards New Therapeutics. <i>Viruses</i> , 2019, 11, 1017.	3.3	54
108	Synthesis of a Threosylâ€œnucleoside Phosphonate. <i>European Journal of Organic Chemistry</i> , 2019, 2019, 6666-6672.	2.4	2
110	Repurposing Quinacrine against Ebola Virus Infection In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	30
111	Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo. <i>Antiviral Research</i> , 2019, 171, 104592.	4.1	22
112	The Curious Case of the Nidovirus Exoribonuclease: Its Role in RNA Synthesis and Replication Fidelity. <i>Frontiers in Microbiology</i> , 2019, 10, 1813.	3.5	130
113	New treatments for Ebola virus disease. <i>BMJ: British Medical Journal</i> , 2019, 366, l5371.	2.3	13

#	ARTICLE	IF	CITATIONS
114	Ebola Virus: Pathogenesis and Countermeasure Development. Annual Review of Virology, 2019, 6, 435-458.	6.7	50
115	Reactive cyclic intermediates in the ProTide prodrugs activation: trapping the elusive pentavalent phosphorane. Organic and Biomolecular Chemistry, 2019, 17, 315-320.	2.8	21
116	A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus. Nature Communications, 2019, 10, 285.	12.8	46
117	Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Research, 2019, 169, 104541.	4.1	398
118	Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Science Translational Medicine, 2019, 11, .	12.4	166
119	T-705 induces lethal mutagenesis in Ebola and Marburg populations in macaques. Antiviral Research, 2019, 170, 104529.	4.1	14
120	Viral Therapeutics. , 2019, , 103-114.		0
121	Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses, 2019, 11, 326.	3.3	478
122	Current status of small molecule drug development for Ebola virus and other filoviruses. Current Opinion in Virology, 2019, 35, 42-56.	5.4	35
123	The (CF <sub>3</sub> C(O)NH)(C <sub>6</sub> H <sub>5</sub> ) <sub>2</sub> CH <sub>2</sub> NH <sub>2</sub> P(O) phosphoric triamide as a novel carrier with excellent efficiency for Cu(II) in a liquid membrane transport system. RSC Advances, 2019, 9, 9153-9159.	3.6	3
124	Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies. Viruses, 2019, 11, 259.	3.3	5
125	Broad-spectrum coronavirus antiviral drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 397-412.	5.0	168
126	Unprecedented Thiocalixarene Fucoclusters as Strong Inhibitors of Ebola cis-Cell Infection and HCMV-gB Glycoprotein/DC-SIGN C-type Lectin Interaction. Bioconjugate Chemistry, 2019, 30, 1114-1126.	3.6	16
127	Advances in respiratory virus therapeutics – A meeting report from the 6th isrv Antiviral Group conference. Antiviral Research, 2019, 167, 45-67.	4.1	137
128	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1450-1453.	2.2	6
129	The Special Pathogens Research Network: Enabling Research Readiness. Health Security, 2019, 17, 35-45.	1.8	11
130	Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. Journal of Feline Medicine and Surgery, 2019, 21, 271-281.	1.6	152
131	Ebola virus disease. Lancet, The, 2019, 393, 936-948.	13.7	305



#	ARTICLE	IF	CITATIONS
132	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. , 2019, , 263-278.		0
133	Ebola Virus Disease. Infectious Disease Clinics of North America, 2019, 33, 953-976.	5.1	36
134	A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. New England Journal of Medicine, 2019, 381, 2293-2303.	27.0	1,171
135	The Joint Mobile Emerging Disease Clinical Capability (JMEDICC) laboratory approach: Capabilities for high-consequence pathogen clinical research. PLoS Neglected Tropical Diseases, 2019, 13, e0007787.	3.0	10
136	Virus and host interactions critical for filoviral RNA synthesis as therapeutic targets. Antiviral Research, 2019, 162, 90-100.	4.1	12
137	Third Tofo Advanced Study Week on Emerging and Re-emerging Viruses, 2018. Antiviral Research, 2019, 162, 142-150.	4.1	3
138	Perspectives towards antiviral drug discovery against Ebola virus. Journal of Medical Virology, 2019, 91, 2029-2048.	5.0	35
139	Polymerases of Coronaviruses. , 2019, , 271-300.		22
140	Two single-enantiomer amidophosphoesters: a database study on the chirality of (O) <sub>2</sub> P(O)(N)-based structures. Acta Crystallographica Section C, Structural Chemistry, 2019, 75, 77-84.	0.5	7
141	Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action. European Journal of Medicinal Chemistry, 2019, 162, 32-50.	5.5	15
142	Confronting the threat of bioterrorism: realities, challenges, and defensive strategies. Lancet Infectious Diseases, The, 2019, 19, e2-e13.	9.1	53
143	Contemporary Anti-Ebola Drug Discovery Approaches and Platforms. ACS Infectious Diseases, 2019, 5, 35-48.	3.8	3
144	The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold. Antiviral Research, 2019, 162, 5-21.	4.1	183
145	Non-gradient and genotype-dependent patterns of RSV gene expression. PLoS ONE, 2020, 15, e0227558.	2.5	16
146	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications, 2020, 11, 222.	12.8	1,376
147	Could 5 <sup>â€²</sup> -N and S ProTide analogues work as prodrugs of antiviral agents?. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126897.	2.2	3
148	Ebola Hemorrhagic Shock Syndrome-on-a-Chip. IScience, 2020, 23, 100765.	4.1	35
149	Ebola virus disease: An emerging and re-emerging viral threat. Journal of Autoimmunity, 2020, 106, 102375.	6.5	79

#	ARTICLE	IF	CITATIONS
150	A Cyclic Phosphoramidate Prodrug of 2-Deoxy-2-Fluoro-2-Methylguanosine for the Treatment of Dengue Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	4
151	Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds. <i>Advances in Pharmacological and Pharmaceutical Sciences</i> , 2020, 2020, 1-10.	1.3	9
152	Development and Clinical Application of Phosphorus-Containing Drugs. <i>Medicine in Drug Discovery</i> , 2020, 8, 100063.	4.5	84
153	Origins and Ownership of Remdesivir. <i>Journal of Law, Medicine and Ethics</i> , 2020, 48, 613-618.	0.9	3
154	Synthesis and biological evaluation of novel flexible nucleoside analogues that inhibit flavivirus replication in vitro. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115713.	3.0	19
155	Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. <i>Nature</i> , 2020, 586, 113-119.	27.8	672
156	Clinical management of lung cancer patients during the outbreak of COVID-19 epidemic. <i>Infectious Agents and Cancer</i> , 2020, 15, 56.	2.6	5
157	A review of medications used to control and improve the signs and symptoms of COVID-19 patients. <i>European Journal of Pharmacology</i> , 2020, 887, 173568.	3.5	3
158	Encephalopathy in COVID-19 patients; viral, parainfectious, or both?. <i>ENeurologicalSci</i> , 2020, 21, 100275.	1.3	36
159	Potential Therapeutic Options for COVID-19. <i>Infectious Microbes &amp; Diseases</i> , 2020, 2, 89-95.	1.3	0
160	Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. <i>Pathogens</i> , 2020, 9, 850.	2.8	16
161	Cyanoamidine Cyclization Approach to Remdesivir's Nucleobase. <i>Organic Letters</i> , 2020, 22, 8430-8435.	4.6	19
162	Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2. <i>Virology</i> , 2020, 550, 61-69.	2.4	33
163	Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26946-26954.	7.1	54
164	A Review of Remdesivir for COVID-19: Data to Date. <i>Cardiology in Review</i> , 2020, 28, 332-334.	1.4	9
165	Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1195-1200.	6.1	40
166	Remdesivir against COVID-19 and Other Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2020, 34, .	13.6	181
167	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. <i>Immunobiology</i> , 2020, 225, 152008.	1.9	65

#	ARTICLE	IF	CITATIONS
168	Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	10
169	SARS-CoV-2, an Underestimated Pathogen of the Nervous System. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2137-2146.	0.6	46
170	Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110668.	5.6	98
171	Emerging strategies on in silico drug development against COVID-19: challenges and opportunities. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 155, 105522.	4.0	25
172	The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. <i>Virology</i> , 2020, 551, 1-9.	2.4	179
173	Development of coumarine derivatives as potent anti-filovirus entry inhibitors targeting viral glycoprotein. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112595.	5.5	10
174	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. <i>ACS Infectious Diseases</i> , 2020, 6, 2304-2318.	3.8	42
175	Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status. <i>SLAS Discovery</i> , 2020, 25, 1097-1107.	2.7	5
176	Minireview of progress in the structural study of SARS-CoV-2 proteins. <i>Current Research in Microbial Sciences</i> , 2020, 1, 53-61.	2.3	43
177	Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection. <i>Frontiers in Pharmacology</i> , 2020, 11, 1013.	3.5	59
178	Molecular targets for COVID-19 drug development: Enlightening Nigerians about the pandemic and future treatment. <i>Biosafety and Health</i> , 2020, 2, 210-216.	2.7	23
179	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. <i>Drug Resistance Updates</i> , 2020, 53, 100719.	14.4	110
180	RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. <i>SLAS Discovery</i> , 2020, 25, 1141-1151.	2.7	131
181	Safety perspectives on presently considered drugs for the treatment of COVID-19. <i>British Journal of Pharmacology</i> , 2020, 177, 4353-4374.	5.4	17
182	Emerging pharmacological therapies for ARDS: COVID-19 and beyond. <i>Intensive Care Medicine</i> , 2020, 46, 2265-2283.	8.2	52
183	Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review. <i>Journal of Thoracic Disease</i> , 2020, 12, 6054-6069.	1.4	14
184	Insights into the Origin, Transmission and Outbreak of Coronavirus Disease (Covid 19): A Recent Study. <i>Asian Journal of Chemistry</i> , 2020, 32, 2403-2415.	0.3	0
185	Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID-19: A scoping review. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2663-2684.	2.4	13

#	ARTICLE	IF	CITATIONS
186	Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. <i>Food and Chemical Toxicology</i> , 2020, 146, 111805.	3.6	31
187	Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2716-2746.	6.4	149
188	SARS coronavirus 2: from genome to infectome. <i>Respiratory Research</i> , 2020, 21, 318.	3.6	62
189	Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. <i>Microorganisms</i> , 2020, 8, 1872.	3.6	25
190	Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. <i>Molecules</i> , 2020, 25, 5695.	3.8	64
191	Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infection. <i>International Journal of Transgender Health</i> , 2020, 13, 608-614.	2.3	11
192	Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. <i>Frontiers in Oncology</i> , 2020, 10, 572329.	2.8	7
193	Coronavirus Infection of the Central Nervous System: Animal Models in the Time of COVID-19. <i>Frontiers in Veterinary Science</i> , 2020, 7, 584673.	2.2	3
194	Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 737-741.	1.1	19
195	&lt;p&gt;A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3215-3222.	4.3	44
196	The Enzymeâ€Free Release of Nucleotides from Phosphoramidates Depends Strongly on the Amino Acid. <i>Angewandte Chemie</i> , 2020, 132, 20329-20335.	2.0	2
197	Remdesivir: A beacon of hope from Ebola virus disease to <sc>COVID</sc>â€19. <i>Reviews in Medical Virology</i> , 2020, 30, 1-13.	8.3	25
198	Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses. <i>Antiviral Research</i> , 2020, 182, 104899.	4.1	40
199	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. <i>International Immunopharmacology</i> , 2020, 88, 106885.	3.8	30
200	Antiviral drugs and plasma therapy used for Covid-19 treatment: a nationwide Turkish algorithm. <i>Drug Metabolism Reviews</i> , 2020, 52, 531-539.	3.6	1
201	<i>In silico</i> designing of multi-epitope vaccine construct against human coronavirus infections. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6903-6917.	3.5	20
202	Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of IK(M) or IK(DR) and in the Stimulation of IMEP. <i>Frontiers in Pharmacology</i> , 2020, 11, 1091.	3.5	22
203	Drugs against SARSâ€CoV â€2: What do we know about their mode of action?. <i>Reviews in Medical Virology</i> , 2020, 30, 1-10.	8.3	30

#	ARTICLE	IF	CITATIONS
204	Potential strategies for combating COVID-19. Archives of Virology, 2020, 165, 2419-2438.	2.1	12
205	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. Virologica Sinica, 2020, 35, 725-733.	3.0	40
206	Mechanisms Underlying Potential Therapeutic Approaches for COVID-19. Frontiers in Immunology, 2020, 11, 1841.	4.8	11
207	Potential repurposed SARS-CoV-2 (COVID-19) infection drugs. RSC Advances, 2020, 10, 26895-26916.	3.6	40
208	Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review. Frontiers in Microbiology, 2020, 11, 1723.	3.5	69
209	Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex. Cell, 2020, 182, 1560-1573.e13.	28.9	360
210	The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2. International Journal of Pharmaceutics, 2020, 588, 119689.	5.2	46
211	Drug Discovery Strategies for SARS-CoV-2. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 127-138.	2.5	83
212	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. Clinical Pharmacokinetics, 2020, 59, 1195-1216.	3.5	28
213	Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection. IScience, 2020, 23, 100999.	4.1	40
214	&lt;p&gt;Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients&lt;/p&gt;. Drug Design, Development and Therapy, 2020, Volume 14, 3001-3013.	4.3	21
215	A Cell-Based Reporter Assay for Screening Inhibitors of MERS Coronavirus RNA-Dependent RNA Polymerase Activity. Journal of Clinical Medicine, 2020, 9, 2399.	2.4	29
216	Antiviral potential of some novel structural analogs of standard drugs repurposed for the treatment of COVID-19. Journal of Biomolecular Structure and Dynamics, 2021, 39, 6676-6688.	3.5	20
217	Remdesivir: Remedy the world is waiting for?. Medical Journal Armed Forces India, 2020, 76, 250-252.	0.8	0
218	Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Molecular Cell, 2020, 79, 710-727.	9.7	326
219	3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoVâ€infectected mice. Science Translational Medicine, 2020, 12, .	12.4	187
220	The Enzymeâ€Free Release of Nucleotides from Phosphoramidates Depends Strongly on the Amino Acid. Angewandte Chemie - International Edition, 2020, 59, 20154-20160.	13.8	17
221	Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. European Journal of Pharmacology, 2020, 885, 173450.	3.5	15

#	ARTICLE	IF	CITATIONS
222	A Chemoenzymatic Synthesis of the (R)-Isomer of the Antiviral Prodrug Remdesivir. <i>Biochemistry</i> , 2020, 59, 3038-3043.	2.5	14
223	Improvement of the C-glycosylation Step for the Synthesis of Remdesivir. <i>Organic Process Research and Development</i> , 2020, 24, 1772-1777.	2.7	26
224	Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir Paradigm. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 613-626.	4.9	39
225	&lt;p&gt;Current Options in the Treatment of COVID-19: A Review&lt;/p&gt;, Risk Management and Healthcare Policy, 2020, Volume 13, 1999-2010.	2.5	8
226	PHARMACOLOGICAL TREATMENTS OF COVID-19 – A REVIEW. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 16-22.	0.3	4
227	Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing. <i>Pharmaceutics</i> , 2020, 12, 1002.	4.5	86
228	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. <i>International Immunopharmacology</i> , 2020, 88, 106980.	3.8	31
229	Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. <i>Science Advances</i> , 2020, 6, .	10.3	128
230	Finding disease modules for cancer and COVID-19 in gene co-expression networks with the Core&Peel method. <i>Scientific Reports</i> , 2020, 10, 17628.	3.3	6
231	Remdesivir: First Approval. <i>Drugs</i> , 2020, 80, 1355-1363.	10.9	176
232	Catalytic Asymmetric Synthesis of the anti-COVID-19 Drug Remdesivir. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 20814-20819.	13.8	73
234	Current perspective on diagnosis, epidemiological assessment, prevention strategies, and potential therapeutic interventions for severe acute respiratory infections caused by 2019 novel coronavirus (SARS-CoV-2). <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3001-3010.	3.3	8
235	Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11085-11099.	6.4	11
236	Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. <i>Nature</i> , 2020, 585, 273-276.	27.8	592
237	Drug repurposing approach to fight COVID-19. <i>Pharmacological Reports</i> , 2020, 72, 1479-1508.	3.3	323
238	Continuous Flow C-Glycosylation via Metal-Halogen Exchange: Process Understanding and Improvements toward Efficient Manufacturing of Remdesivir. <i>Organic Process Research and Development</i> , 2020, 24, 2362-2368.	2.7	29
239	Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. <i>Journal of Biological Chemistry</i> , 2020, 295, 16156-16165.	3.4	120
240	Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. <i>BMJ Open</i> , 2020, 10, e041437.	1.9	46

#	ARTICLE	IF	CITATIONS
241	Possibility of magnesium supplementation for supportive treatment in patients with COVID-19. <i>European Journal of Pharmacology</i> , 2020, 886, 173546.	3.5	76
242	A Systematic Review of COVID-19 Infection in Kidney Transplant Recipients: A Universal Effort to Preserve Patients' Lives and Allografts. <i>Journal of Clinical Medicine</i> , 2020, 9, 2986.	2.4	44
243	Catalytic Asymmetric Synthesis of the anti-COVID-19 Drug Remdesivir. <i>Angewandte Chemie</i> , 2020, 132, 21000-21005.	2.0	11
244	Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3359-3365.	3.0	41
245	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13205-13227.	6.4	40
246	Viral Vectors Applied for RNAi-Based Antiviral Therapy. <i>Viruses</i> , 2020, 12, 924.	3.3	22
247	Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. <i>Frontiers in Microbiology</i> , 2020, 11, 1818.	3.5	81
248	Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?. <i>Clinical and Molecular Allergy</i> , 2020, 18, 17.	1.8	27
249	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. <i>Frontiers in Pharmacology</i> , 2020, 11, 582025.	3.5	14
250	Pathophysiology and treatment strategies for COVID-19. <i>Journal of Translational Medicine</i> , 2020, 18, 353.	4.4	71
251	SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. <i>IUBMB Life</i> , 2020, 72, 2313-2330.	3.4	10
252	Click-Free Synthesis of a Multivalent Tricyclic Peptide as a Molecular Transporter. <i>Pharmaceutics</i> , 2020, 12, 842.	4.5	7
253	For Whom a Puddle Is the Sea? Adsorption of Organic Guests on Hydrated MCM-41 Silica. <i>Langmuir</i> , 2020, 36, 11383-11392.	3.5	19
254	COVID-19 Pandemic: from Molecular Biology, Pathogenesis, Detection, and Treatment to Global Societal Impact. <i>Current Pharmacology Reports</i> , 2020, 6, 212-227.	3.0	31
255	COVID-19 Therapeutic Options Under Investigation. <i>Frontiers in Pharmacology</i> , 2020, 11, 1196.	3.5	65
256	Treatment Options for COVID-19: A Review. <i>Frontiers in Medicine</i> , 2020, 7, 480.	2.6	75
257	COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. <i>PLoS Pathogens</i> , 2020, 16, e1008762.	4.7	194
258	Recent successes in therapeutics for Ebola virus disease: no time for complacency. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e231-e237.	9.1	42

#	ARTICLE	IF	CITATIONS
259	Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 616341.	3.5	83
260	A New Crystal Form of the SARS-CoV-2 Receptor Binding Domain: CR3022 Complex—An Ideal Target for In-Crystal Fragment Screening of the ACE2 Binding Site Surface. <i>Frontiers in Pharmacology</i> , 2020, 11, 615211.	3.5	7
261	Biocatalysis in the Swiss Manufacturing Environment. <i>Catalysts</i> , 2020, 10, 1420.	3.5	13
262	Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. <i>Cell Discovery</i> , 2020, 6, 96.	6.7	85
263	Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations. <i>Journal of Physical Chemistry B</i> , 2020, 124, 11337-11348.	2.6	71
264	Reverse C-glycosidase reaction provides C-nucleotide building blocks of xenobiotic nucleic acids. <i>Nature Communications</i> , 2020, 11, 6270.	12.8	12
265	Products of Oxidative Guanine Damage Form Base Pairs with Guanine. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7645.	4.1	14
266	Coronavirus pandemic: treatment and future prevention. <i>Future Microbiology</i> , 2020, 15, 1507-1521.	2.0	2
267	Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics. <i>Cell Host and Microbe</i> , 2020, 28, 638-645.	11.0	30
268	In-line treatments and clinical initiatives to fight against COVID-19 outbreak. <i>Respiratory Medicine</i> , 2022, 191, 106192.	2.9	15
269	Coronavirus in human diseases: Mechanisms and advances in clinical treatment. <i>MedComm</i> , 2020, 1, 270-301.	7.2	22
270	New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	59
271	COVID-19: the epidemiology and treatment. <i>British Journal of Hospital Medicine (London, England:)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50.5	0.5	9
272	Recent Advances in the Chemical Synthesis and Evaluation of Anticancer Nucleoside Analogues. <i>Molecules</i> , 2020, 25, 2050.	3.8	67
273	CNS penetration of potential anti-COVID-19 drugs. <i>Journal of Neurology</i> , 2020, 267, 1880-1882.	3.6	37
274	Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. <i>ACS Central Science</i> , 2020, 6, 672-683.	11.3	684
275	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1772-1777.	3.0	69
276	The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. <i>FASEB Journal</i> , 2020, 34, 7253-7264.	0.5	83



#	ARTICLE	IF	CITATIONS
277	The Rationale for Potential Pharmacotherapy of COVID-19. <i>Pharmaceuticals</i> , 2020, 13, 96.	3.8	40
278	COVID-19 Pandemic: Prevention and Protection Measures to Be Adopted at the Workplace. <i>Sustainability</i> , 2020, 12, 3603.	3.2	183
279	The liver in times of COVID-19: What hepatologists should know. <i>Annals of Hepatology</i> , 2020, 19, 353-358.	1.5	72
280	The Cellular Protein CAD is Recruited into Ebola Virus Inclusion Bodies by the Nucleoprotein NP to Facilitate Genome Replication and Transcription. <i>Cells</i> , 2020, 9, 1126.	4.1	20
281	A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 1137-1152.	3.0	37
282	Covid-19 Pandemic and Current Medical Interventions. <i>Archives of Medical Research</i> , 2020, 51, 473-481.	3.3	11
283	Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan. <i>Global Health &amp; Medicine</i> , 2020, 2, 96-101.	1.4	20
284	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. <i>Military Medical Research</i> , 2020, 7, 22.	3.4	57
285	A global treatments for coronaviruses including COVID-19. <i>Journal of Cellular Physiology</i> , 2020, 235, 9133-9142.	4.1	91
286	The current understanding and potential therapeutic options to combat COVID-19. <i>Life Sciences</i> , 2020, 254, 117765.	4.3	72
287	Novel coronavirus 2019 (COVID-19). <i>Medicine (United States)</i> , 2020, 99, e20207.	1.0	44
288	SARS-CoV-2 RNA polymerase as target for antiviral therapy. <i>Journal of Translational Medicine</i> , 2020, 18, 185.	4.4	64
289	Rapid review for the anti-coronavirus effect of remdesivir. <i>Drug Discoveries and Therapeutics</i> , 2020, 14, 73-76.	1.5	48
290	SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1750-1765.	3.0	175
291	Evaluating the potential of different inhibitors on RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2: A molecular modeling approach. <i>Medical Journal Armed Forces India</i> , 2021, 77, S373-S378.	0.8	15
292	Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. <i>Life Sciences</i> , 2020, 256, 117883.	4.3	114
293	Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus. <i>Journal of Infectious Diseases</i> , 2020, 222, 1894-1901.	4.0	41
294	Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply. <i>Organic Process Research and Development</i> , 2020, 24, 940-976.	2.7	77

#	ARTICLE	IF	CITATIONS
295	Current evidence for directed and supportive investigational therapies against COVID-19. African Journal of Thoracic and Critical Care Medicine, 2020, 26, 45.	0.6	1
296	Combating biothreat pathogens: ongoing efforts for countermeasure development and unique challenges. , 2020, , 171-222.		0
297	High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment. International Journal of Biological Macromolecules, 2020, 160, 1-17.	7.5	75
298	Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. , 2020, 213, 107587.		216
299	Topological Indices of Some Chemical Structures Applied for the Treatment of COVID-19 Patients. Polycyclic Aromatic Compounds, 2022, 42, 1220-1234.	2.6	64
300	Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit. AAPS Journal, 2020, 22, 77.	4.4	98
301	Development of a Large-Scale Cyanation Process Using Continuous Flow Chemistry En Route to the Synthesis of Remdesivir. Organic Process Research and Development, 2020, 24, 2113-2121.	2.7	51
302	Potential specific therapies in COVID-19. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662092685.	2.6	18
303	A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells, 2020, 9, 1267.	4.1	400
304	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal of Medicine, 2020, 383, 1827-1837.	27.0	1,152
305	NOVEL CORONAVIRUS (2019-nCoV): DISEASE BRIEFINGS. Asian Journal of Pharmaceutical and Clinical Research, 0, , 22-27.	0.3	2
306	COVID-19: Emergence, Spread, Possible Treatments, and Global Burden. Frontiers in Public Health, 2020, 8, 216.	2.7	168
307	Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China. Virus Research, 2020, 286, 198057.	2.2	57
308	Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition. Frontiers in Microbiology, 2020, 11, 1105.	3.5	23
309	Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase. Journal of Physical Chemistry B, 2020, 124, 6955-6962.	2.6	105
310	Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). Viruses, 2020, 12, 628.	3.3	55
311	Possible therapeutic agents for COVID-19: a comprehensive review. Expert Review of Anti-Infective Therapy, 2020, 18, 1005-1020.	4.4	24
313	nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. Frontiers in Cell and Developmental Biology, 2020, 8, 616.	3.7	56

#	ARTICLE	IF	CITATIONS
314	Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, e141-e144.	1.5	4
315	Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1361-1366.	2.8	137
316	Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7211-7225.	6.4	16
317	Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3922.	4.1	148
318	Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. <i>JAMA Pediatrics</i> , 2020, 174, e202422.	6.2	35
319	A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. <i>European Journal of Medicinal Chemistry</i> , 2020, 201, 112527.	5.5	85
320	Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2020, 10, e039159.	1.9	8
321	Synthesis of Remdesivir (GS-5734) – A Candidate for the Treatment of Ebola and COVID-19 Infections. <i>Synfacts</i> , 2020, 16, 0765.	0.0	0
322	The broad-spectrum antiviral recommendations for drug discovery against COVID-19. <i>Drug Metabolism Reviews</i> , 2020, 52, 408-424.	3.6	14
324	Oral Methioninase for Covid-19 Methionine-restriction Therapy. <i>In Vivo</i> , 2020, 34, 1593-1596.	1.3	12
325	Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1384-1386.	6.1	142
326	COVID-19 infection: the China and Italy perspectives. <i>Cell Death and Disease</i> , 2020, 11, 438.	6.3	76
327	Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. <i>Scientific Reports</i> , 2020, 10, 9294.	3.3	82
328	Uncovering the chemistry of C–C bond formation in C-nucleoside biosynthesis: crystal structure of a C-glycoside synthase/PRPP complex. <i>Chemical Communications</i> , 2020, 56, 7617-7620.	4.1	15
329	The continued epidemic threat of SARS-CoV-2 and implications for the future of global public health. <i>Current Opinion in Virology</i> , 2020, 40, 37-40.	5.4	17
330	A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV). <i>Journal of Medical Virology</i> , 2020, 92, 1542-1548.	5.0	92
331	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. <i>Cell Research</i> , 2020, 30, 269-271.	12.0	5,527
332	Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6771-6776.	7.1	735

#	ARTICLE	IF	CITATIONS
333	SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. <i>International Journal of Biological Sciences</i> , 2020, 16, 1678-1685.	6.4	751
334	Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 258-271.	2.5	20
335	COVID-19: what has been learned and to be learned about the novel coronavirus disease. <i>International Journal of Biological Sciences</i> , 2020, 16, 1753-1766.	6.4	579
336	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa105.	0.9	255
337	Controversial treatments: An updated understanding of the coronavirus disease 2019. <i>Journal of Medical Virology</i> , 2020, 92, 1441-1448.	5.0	73
338	Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors. <i>MAbs</i> , 2020, 12, 1742457.	5.2	18
339	Remdesivir as a possible therapeutic option for the COVID-19. <i>Travel Medicine and Infectious Disease</i> , 2020, 34, 101615.	3.0	250
340	Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. <i>Journal of Medical Virology</i> , 2020, 92, 568-576.	5.0	1,135
341	Arguments in favour of remdesivir for treating SARS-CoV-2 infections. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105933.	2.5	263
342	Clinical targeting of HIV capsid protein with a long-acting small molecule. <i>Nature</i> , 2020, 584, 614-618.	27.8	192
343	GS-5734: a potentially approved drug by FDA against SARS-Cov-2. <i>New Journal of Chemistry</i> , 2020, 44, 12417-12429.	2.8	24
344	Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2977-2980.	3.0	90
345	Remdesivir "Bringing Hope for COVID-19 Treatment. <i>Scientia Pharmaceutica</i> , 2020, 88, 29.	2.0	24
346	Review of the SARS-CoV-2 in Wuhan and Analysis as Well as Prediction of Therapeutic Drugs. <i>Viral Immunology</i> , 2020, 34, 291-299.	1.3	0
347	Endemic and Emerging Coronavirus Pulmonary Infections. <i>American Journal of the Medical Sciences</i> , 2020, 360, 728-732.	1.1	0
348	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>Cell Reports</i> , 2020, 32, 107940.	6.4	412
349	Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. <i>European Journal of Pharmacology</i> , 2020, 883, 173348.	3.5	55
350	Pandemic COVID-19: Current status and challenges of antiviral therapies. <i>Genes and Diseases</i> , 2020, 7, 502-519.	3.4	11

#	ARTICLE	IF	CITATIONS
351	Ebola Virus Dose Response Model for Aerosolized Exposures: Insights from Primate Data. <i>Risk Analysis</i> , 2020, 40, 2390-2398.	2.7	3
352	Progress in the Research and Development of Anti-COVID-19 Drugs. <i>Frontiers in Public Health</i> , 2020, 8, 365.	2.7	21
353	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 694-699.	0.6	30
354	Pharmacotherapeutics Advice in Guidelines for COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 950.	3.5	6
355	Emerging Prevention and Treatment Strategies to Control COVID-19. <i>Pathogens</i> , 2020, 9, 501.	2.8	22
356	SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. <i>Vaccines</i> , 2020, 8, 335.	4.4	43
357	Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data. <i>Molecular Omics</i> , 2020, 16, 474-491.	2.8	33
358	Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. <i>Clinical and Translational Science</i> , 2020, 13, 896-906.	3.1	183
359	A prospect on the use of antiviral drugs to control local outbreaks of COVID-19. <i>BMC Medicine</i> , 2020, 18, 191.	5.5	47
360	Redox-Neutral P(O)â€“N Coupling between P(O)â€“H Compounds and Azides via Dual Copper and Photoredox Catalysis. <i>Organic Letters</i> , 2020, 22, 6143-6149.	4.6	27
361	Current therapies under investigation for COVID-19: potential COVID-19 treatments. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 483-489.	1.4	6
362	Architecture and selfâ€“assembly of the <sc>SARSâ€“CoV</sc>â€“2 nucleocapsid protein. <i>Protein Science</i> , 2020, 29, 1890-1901.	7.6	218
363	Outbreak of COVID-19: An emerging global pandemic threat. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110499.	5.6	48
364	The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. <i>Journal of Biological Chemistry</i> , 2020, 295, 4773-4779.	3.4	659
365	Emerging small and large molecule therapeutics for respiratory syncytial virus. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 285-294.	4.1	14
366	Antivirals in medical biodefense. <i>Virus Genes</i> , 2020, 56, 150-167.	1.6	20
367	Ebola virus disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 13.	30.5	340
368	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. <i>Life Sciences</i> , 2020, 248, 117477.	4.3	546

#	ARTICLE	IF	CITATIONS
369	Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases. <i>Virologica Sinica</i> , 2020, 35, 253-255.	3.0	52
370	Modeling Challenges of Ebola Virusâ€™ Host Dynamics during Infection and Treatment. <i>Viruses</i> , 2020, 12, 106.	3.3	7
371	Stericallyâ€Controlled Selfâ€Immolation in Phosphoramidate Linkers Triggered by Light. <i>European Journal of Organic Chemistry</i> , 2020, 2020, 897-906.	2.4	6
372	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2020, 395, 1569-1578.	13.7	2,875
373	Remdesivir in covid-19. <i>BMJ, The</i> , 2020, 369, m1610.	6.0	91
374	Treatment Considerations for COVID-19. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1454-1466.	3.0	79
375	Tolcapone Potently Inhibits Seminal Amyloid Fibrils Formation and Blocks Entry of Ebola Pseudoviruses. <i>Frontiers in Microbiology</i> , 2020, 11, 504.	3.5	3
376	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. <i>Pathogens</i> , 2020, 9, 331.	2.8	198
377	Will the antimalarial drug take over to combat COVID-19?. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2020, , 1-4.	1.6	4
378	Candidate drugs against SARS-CoV-2 and COVID-19. <i>Pharmacological Research</i> , 2020, 157, 104859.	7.1	426
379	Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. <i>Science</i> , 2020, 368, 1499-1504.	12.6	950
380	Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. <i>Pharmacotherapy</i> , 2020, 40, 416-437.	2.6	166
381	Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. <i>Antiviral Research</i> , 2020, 178, 104793.	4.1	271
382	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. <i>Clinical Immunology</i> , 2020, 215, 108409.	3.2	217
383	Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105950.	2.5	131
384	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. <i>JHEP Reports</i> , 2020, 2, 100113.	4.9	378
385	Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 488-492.	3.1	68
386	Treatment options for COVID-19: The reality and challenges. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 436-443.	3.1	393

#	ARTICLE	IF	CITATIONS
387	Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. <i>One Health</i> , 2020, 9, 100128.	3.4	157
388	COVID-19: A promising cure for the global panic. <i>Science of the Total Environment</i> , 2020, 725, 138277.	8.0	464
389	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. <i>Travel Medicine and Infectious Disease</i> , 2020, 35, 101647.	3.0	227
390	Halting coronavirus polymerase. <i>Journal of Biological Chemistry</i> , 2020, 295, 4780-4781.	3.4	4
391	Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. <i>Journal of Biological Chemistry</i> , 2020, 295, 6785-6797.	3.4	752
392	Structure of the RNA-dependent RNA polymerase from COVID-19 virus. <i>Science</i> , 2020, 368, 779-782.	12.6	1,228
393	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	886
394	COVID-19 Drug Discovery Using Intensive Approaches. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2839.	4.1	55
395	COVID-19 pandemic—a focused review for clinicians. <i>Clinical Microbiology and Infection</i> , 2020, 26, 842-847.	6.0	289
396	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, , .	5.8	708
397	D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1239-1248.	12.0	65
398	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1043-1049.	2.0	30
399	A deadly spillover: SARS-CoV-2 outbreak. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 481-485.	5.0	29
400	Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. <i>Nature Medicine</i> , 2020, 26, 861-868.	30.7	327
401	Delayed Initiation of Remdesivir in a COVID-19 Positive Patient. <i>Pharmacotherapy</i> , 2020, 40, 592-598.	2.6	59
402	Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 363-382.	8.7	311
403	Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 3771-3779.	3.5	30
404	RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. <i>Journal of Medical Virology</i> , 2021, 93, 300-310.	5.0	82

#	ARTICLE	IF	CITATIONS
405	An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine. International Journal of Clinical Practice, 2021, 75, e13825.	1.7	6
406	Insights on 3D Structures of Potential Drug-targeting Proteins of SARS-CoV-2: Application of Cavity Search and Molecular Docking. Molecular Informatics, 2021, 40, e2000096.	2.5	13
407	Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned. Vascular, 2021, 29, 220-227.	0.9	1
408	Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2. Angewandte Chemie - International Edition, 2021, 60, 9789-9802.	13.8	50
409	Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2. Angewandte Chemie, 2021, 133, 9873-9886.	2.0	9
410	<scp>SARS-CoV-2</scp> (<scp>COVID-19</scp>): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. Cell Biochemistry and Function, 2021, 39, 10-28.	2.9	13
411	Remdesivir and its antiviral activity against COVID-19: A systematic review. Clinical Epidemiology and Global Health, 2021, 9, 123-127.	1.9	143
412	Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. Biochemical Pharmacology, 2021, 183, 114296.	4.4	79
413	Improving target assessment in biomedical research: the GOT-IT recommendations. Nature Reviews Drug Discovery, 2021, 20, 64-81.	46.4	86
414	Toward a Molecular Basis of Cellular Nucleoside Transport in Humans. Chemical Reviews, 2021, 121, 5336-5358.	47.7	19
415	Off-Target <i>In Vitro</i> Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	38
416	Nanotechnology for virus treatment. Nano Today, 2021, 36, 101031.	11.9	58
417	An AZT Analog with Strongly Pairing Ethynylpyridone Nucleobase and Its Antiviral Activity against HSV1. Chemistry and Biodiversity, 2021, 18, e2000937.	2.1	7
418	A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2. International Immunopharmacology, 2021, 90, 107232.	3.8	27
419	Challenges and stepwise fit-for-purpose optimization for bioanalyses of remdesivir metabolites nucleotide monophosphate and triphosphate in mouse tissues using LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113806.	2.8	9
420	Cryo-EM Structures Reveal Transcription Initiation Steps by Yeast Mitochondrial RNA Polymerase. Molecular Cell, 2021, 81, 268-280.e5.	9.7	15
421	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. Medicinal Research Reviews, 2021, 41, 1375-1426.	10.5	28
422	Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1). Annals of Internal Medicine, 2021, 174, 229-236.	3.9	3



#	ARTICLE	IF	CITATIONS
423	The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 63-71.	2.1	30
424	Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111035.	5.6	24
425	Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches. <i>Bioorganic Chemistry</i> , 2021, 106, 104488.	4.1	22
426	SARS-CoV-2: a new dimension to our understanding of coronaviruses. <i>International Microbiology</i> , 2021, 24, 19-24.	2.4	25
427	Decoding the silent walk of COVID-19: Halting its spread using old bullets. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 110891.	5.6	1
428	Pharmacokinetics under the COVID-19 storm. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	2.4	12
429	Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. <i>International Immunopharmacology</i> , 2021, 90, 107228.	3.8	24
430	Computational and theoretical exploration for clinical suitability of Remdesivir drug to SARS-CoV-2. <i>European Journal of Pharmacology</i> , 2021, 890, 173642.	3.5	8
431	Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs. <i>International Journal of Biological Macromolecules</i> , 2021, 168, 272-278.	7.5	27
432	Repurposing drugs for the management of COVID-19. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 295-307.	5.0	49
433	Key advances in biocatalytic phosphorylations in the last two decades: Biocatalytic syntheses in vitro and biotransformations in vivo (in humans). <i>Biotechnology Journal</i> , 2021, 16, e2000090.	3.5	11
434	Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication. <i>Journal of Proteome Research</i> , 2021, 20, 49-59.	3.7	32
435	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of <i>in vitro</i> , <i>in vivo</i> , and clinical trials. <i>Theranostics</i> , 2021, 11, 1207-1231.	10.0	24
436	Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. <i>ACS Infectious Diseases</i> , 2021, 7, 1317-1331.	3.8	37
437	Response to: Status of Remdesivir: Not Yet Beyond Question!. <i>Archives of Medical Research</i> , 2021, 52, 104-106.	3.3	7
438	Remdesivir: From Ebola to COVID-19. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 145-150.	2.1	39
439	Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2. <i>Journal of Natural Products</i> , 2021, 84, 161-182.	3.0	38
440	Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2020, 11, 592908.	3.5	68

#	ARTICLE	IF	CITATIONS
441	ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response. <i>Cell Stem Cell</i> , 2021, 28, 331-342.e5.	11.1	156
442	A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 89-99.	2.5	21
443	Biocatalytic routes to anti-viral agents and their synthetic intermediates. <i>Chemical Society Reviews</i> , 2021, 50, 1968-2009.	38.1	39
444	Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment. <i>Drug Research</i> , 2021, 71, 138-148.	1.7	10
445	Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2170-2185.	2.4	15
446	Recent progress of antiviral therapy for coronavirus disease 2019. <i>European Journal of Pharmacology</i> , 2021, 890, 173646.	3.5	32
447	The recent outbreaks of human coronaviruses: A medicinal chemistry perspective. <i>Medicinal Research Reviews</i> , 2021, 41, 72-135.	10.5	31
448	Review of Ebola virus disease in children – how far have we come?. <i>Paediatrics and International Child Health</i> , 2021, 41, 12-27.	1.0	5
449	COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 113-131.	3.8	16
450	Different Versions of Atom-Bond Connectivity Indices of Some Molecular Structures: Applied for the Treatment and Prevention of COVID-19. <i>Polycyclic Aromatic Compounds</i> , 2022, 42, 3748-3761.	2.6	6
451	Safe-in-Man Broad Spectrum Antiviral Agents. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 313-337.	1.6	1
452	COVID-19: inflammatory responses, structure-based drug design and potential therapeutics. <i>Molecular Diversity</i> , 2022, 26, 629-645.	3.9	15
453	Therapeutic targets and potential agents for the treatment of COVID-19. <i>Medicinal Research Reviews</i> , 2021, 41, 1775-1797.	10.5	21
454	RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 6039-6051.	3.5	29
455	Therapeutic and Diagnostic Approaches for SARS-CoV-2. <i>Voice of the Publisher</i> , 2021, 07, 63-79.	0.2	1
456	Drug Combinations. , 2021, , .		0
457	Emerging therapeutics in the management of COVID-19. <i>World Journal of Virology</i> , 2021, 10, 1-29.	2.9	7
458	Intense bitterness of molecules: Machine learning for expediting drug discovery. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 568-576.	4.1	31

#	ARTICLE	IF	CITATIONS
459	Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100045.	3.6	20
460	Two polymorphs of remdesivir: crystal structure, solubility, and pharmacokinetic study. <i>CrystEngComm</i> , 2021, 23, 2923-2927.	2.6	5
461	The role of chemical biology in the fight against SARS-CoV-2. <i>Biochemical Journal</i> , 2021, 478, 157-177.	3.7	2
463	Probing remdesivir nucleotide analogue insertion to SARS-CoV-2 RNA dependent RNA polymerase in viral replication. <i>Molecular Systems Design and Engineering</i> , 2021, 6, 888-902.	3.4	11
464	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Associated Urogenital Disease: A Current Update. <i>World Journal of Men's Health</i> , 2021, 39, 444.	3.3	0
465	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. , 2021, , 27-89.		0
466	Human Viruses: Infection, Prevention and Potential Target(s) for Therapy. <i>Comprehensive Review</i> , 2021, , 3-54.		0
467	Computational Characterizations of the Interactions Between the Pontacyl Violet 6R and Exoribonuclease as a Potential Drug Target Against SARS-CoV-2. <i>Frontiers in Chemistry</i> , 2020, 8, 627340.	3.6	2
468	Diverse synthetic approaches towards C1 <sup>α</sup> -branched acyclic nucleoside phosphonates. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 6958-6963.	2.8	1
469	Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 606429.	2.6	45
470	A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.. <i>Ahi Evran Medical Journal</i> , 0, , .	0.1	0
471	Ebolavirus and Other Filoviruses. , 2021, , .		0
472	<i>In Silico</i> Exploration of Phytoconstituents From <i>Phyllanthus emblica</i> and <i>Aegle marmelos</i> as Potential Therapeutics Against SARS-CoV-2 RdRp. <i>Bioinformatics and Biology Insights</i> , 2021, 15, 117793222110274.	2.0	14
473	Transcriptomic Approaches in Understanding SARS-CoV-2 Infection. , 2021, , 221-239.		0
474	Molecular mechanisms and pharmacological interventions in the replication cycle of human coronaviruses. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200212.	1.3	11
475	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. <i>Comparative Medicine</i> , 2021, 71, 342-358.	1.0	3
477	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. <i>AAPS Journal</i> , 2021, 23, 14.	4.4	291
478	The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract. <i>Emerging Microbes and Infections</i> , 2021, 10, 481-492.	6.5	37

#	ARTICLE	IF	CITATIONS
479	Synthesis of Aryl or Heteroaryl <i>C</i> -Nucleosides by Direct Coupling of a Carbohydrate Moiety with a Preformed Aglycon Unit. <i>Chinese Journal of Organic Chemistry</i> , 2021, 41, 3948.	1.3	2
480	Flash Chemistry Approach to Organometallic <i>C</i> -Glycosylation for the Synthesis of Remdesivir. <i>Organic Process Research and Development</i> , 2021, 25, 1015-1021.	2.7	25
481	Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. <i>Nano Today</i> , 2021, 36, 101051.	11.9	61
482	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. <i>Frontiers in Pharmacology</i> , 2020, 11, 583914.	3.5	8
483	Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements. <i>3 Biotech</i> , 2021, 11, 110.	2.2	2
484	Technological exaptation and crisis management: Evidence from COVID-19 outbreaks. <i>R and D Management</i> , 2021, 51, 381-392.	5.3	88
485	A modeling framework for embedding-based predictions for compound-viral protein activity. <i>Bioinformatics</i> , 2021, 37, 2544-2555.	4.1	5
486	Identification of Novel SARS-CoV-2 Inhibitors: A Structure-Based Virtual Screening Approach. <i>Journal of Chemistry</i> , 2021, 2021, 1-7.	1.9	18
487	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. <i>Frontiers in Immunology</i> , 2020, 11, 616595.	4.8	20
488	Characterization of Ebola Virus Risk to Bedside Providers in an Intensive Care Environment. <i>Microorganisms</i> , 2021, 9, 498.	3.6	1
489	A Biochemical Perspective of the Nonstructural Proteins (NSPs) and the Spike Protein of SARS CoV-2. <i>Protein Journal</i> , 2021, 40, 260-295.	1.6	24
491	Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs. <i>Pharmacogenomics Journal</i> , 2021, 21, 275-284.	2.0	32
492	Flavonol morin targets host ACE2, IMP-1, PARP-1 and viral proteins of SARS-CoV-2, SARS-CoV and MERS-CoV critical for infection and survival: a computational analysis. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 5515-5546.	3.5	16
493	A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 590154.	3.5	8
494	Artificially expanded genetic information systems (AEGISs) as potent inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 6381-6397.	3.5	14
495	Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2785-2793.	6.4	92
496	Prevalence of Foreign Body Aspiration in Children in a Tertiary Care Hospital. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 111-115.	0.4	3
497	A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. <i>Frontiers in Pharmacology</i> , 2021, 12, 576448.	3.5	11

#	ARTICLE	IF	CITATIONS
498	Practical Remdesivir Synthesis through One-Pot Organocatalyzed Asymmetric (<i>S</i>)-P-Phosphoramidation. <i>Journal of Organic Chemistry</i> , 2021, 86, 4977-4985.	3.2	16
499	A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19). <i>Bulletin of the National Research Centre</i> , 2021, 45, 36.	1.8	25
500	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). <i>Current Pharmaceutical Design</i> , 2021, 27, 115-126.	1.9	13
501	On Topological Indices of Remdesivir Compound Used in Treatment of Corona Virus (COVID 19). <i>Polycyclic Aromatic Compounds</i> , 2022, 42, 4300-4316.	2.6	25
502	Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinoplastid agents. <i>European Journal of Medicinal Chemistry</i> , 2021, 212, 113101.	5.5	14
503	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. <i>Frontiers in Medicine</i> , 2021, 8, 606755.	2.6	4
504	Structural differences/similarities of diastereotopic groups in three new chiral phosphoramides. <i>Acta Crystallographica Section C, Structural Chemistry</i> , 2021, 77, 186-196.	0.5	0
505	Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. <i>Microorganisms</i> , 2021, 9, 566.	3.6	13
506	Phylogenetic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 7726-7743.	3.5	5
507	The Situation of Small Molecules Targeting Key Proteins in combatting SARS-CoV-2: Synthesis, Metabolic Pathway, Mechanism of Action, and Potential Therapeutic Applications. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 273-311.	2.4	3
508	Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106274.	2.5	51
509	Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies. <i>Analytical Biochemistry</i> , 2021, 617, 114118.	2.4	27
510	Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. <i>International Journal of Biological Macromolecules</i> , 2021, 172, 524-541.	7.5	123
511	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 429-460.	2.0	22
512	A novel cell culture system modeling the SARS-CoV-2 life cycle. <i>PLoS Pathogens</i> , 2021, 17, e1009439.	4.7	102
513	PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. <i>Clinical Infectious Diseases</i> , 2021, 73, 1849-1856.	5.8	24
514	Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009300.	3.0	6
515	Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomein. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 603-609.	2.8	29

#	ARTICLE	IF	CITATIONS
516	Targeting Ebola virus replication through pharmaceutical intervention. Expert Opinion on Investigational Drugs, 2021, 30, 201-226.	4.1	11
517	Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clinical Pharmacokinetics, 2021, 60, 569-583.	3.5	79
518	COVID-19 into Chemical Science Perspective: Chemical Preventive Measures and Drug Development. ChemistrySelect, 2021, 6, 2010-2028.	1.5	6
519	Remdesivir for COVID-19: Why Not Dose Higher?. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	6
520	SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opinion on Therapeutic Patents, 2021, 31, 325-337.	5.0	84
521	Antivirals with common targets against highly pathogenic viruses. Cell, 2021, 184, 1604-1620.	28.9	78
522	Significant Inhibition of Porcine Epidemic Diarrhea Virus In Vitro by Remdesivir, Its Parent Nucleoside and Î²-d-N4-hydroxycytidine. Virologica Sinica, 2021, 36, 997-1005.	3.0	12
523	Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy. Food and Chemical Toxicology, 2021, 149, 111998.	3.6	37
524	Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate. Journal of Organic Chemistry, 2021, 86, 5065-5072.	3.2	15
526	Coronaviruses. Expert Opinion on Therapeutic Patents, 2021, 31, 291-294.	5.0	7
527	Combination therapy protects macaques against advanced Marburg virus disease. Nature Communications, 2021, 12, 1891.	12.8	37
528	Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters. Pharmaceutics, 2021, 13, 369.	4.5	14
529	Remdesivir: An Antiviral Still Seeking a Raison d'ÃŠtre. Clinical Infectious Diseases, 2021, 73, 1857-1859.	5.8	0
530	Drug Re-purposing Approach and Potential Therapeutic Strategies to Treat COVID-19. Mini-Reviews in Medicinal Chemistry, 2021, 21, 704-723.	2.4	7
531	Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. Journal of Infection and Public Health, 2021, 14, 331-346.	4.1	12
532	Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	64
533	Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	27
534	Reply to Yan and Muller, â€œRemdesivir for COVID-19: Why Not Dose Higher?â€. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	2

#	ARTICLE	IF	CITATIONS
535	TREATMENT MODALITIES OF THE COVID-19 PANDEMIC THROUGH REPURPOSED DRUGS AND STATUS OF VACCINES. International Journal of Applied Pharmaceutics, 0, , 48-58.	0.3	4
536	Cyclodextrins in Antiviral Therapeutics and Vaccines. Pharmaceutics, 2021, 13, 409.	4.5	24
537	A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. Journal of Antimicrobial Chemotherapy, 2021, 76, 1865-1873.	3.0	9
538	Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics. Pharmaceutics, 2021, 13, 545.	4.5	17
539	Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. Cells, 2021, 10, 1052.	4.1	26
540	Prodrugs of a 1-β-D-Cyano-4-Aza-7,9-dideazaadenosine Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. Journal of Medicinal Chemistry, 2021, 64, 5001-5017.	6.4	40
541	Current diagnostic and therapeutic strategies for COVID-19. Journal of Pharmaceutical Analysis, 2021, 11, 129-137.	5.3	11
542	Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Reports, 2021, 35, 108959.	6.4	176
543	Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. Viruses, 2021, 13, 667.	3.3	79
544	Coronavirus genomic nsp14 ExoN, structure, role, mechanism, and potential application as a drug target. Journal of Medical Virology, 2021, 93, 4258-4264.	5.0	45
546	iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility. FEBS Open Bio, 2021, 11, 1452-1464.	2.3	17
547	Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71. Viruses, 2021, 13, 774.	3.3	9
548	Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nature Communications, 2021, 12, 2295.	12.8	130
549	Fast and efficient purification of SARS-CoV-2 RNA dependent RNA polymerase complex expressed in Escherichia coli. PLoS ONE, 2021, 16, e0250610.	2.5	5
550	The treatment of SARS-CoV2 with antivirals and mitigation of the cytokine storm syndrome: the role of gene expression. Genome, 2021, 64, 400-415.	2.0	0
551	Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. British Journal of Pharmacology, 2021, 178, 2339-2350.	5.4	74
552	COVID-19: The Unprecedented Malady- A Holistic Review. Coronaviruses, 2021, 2, 172-181.	0.3	0
553	Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2. Frontiers in Molecular Biosciences, 2021, 8, 645216.	3.5	20

#	ARTICLE	IF	CITATIONS
554	Drug metabolism in the lungs: opportunities for optimising inhaled medicines. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 611-625.	3.3	27
555	Differences in Interactions Within Viral Replication Complexes of SARS-CoV-2 (COVID-19) and SARS-CoV Coronaviruses Control RNA Replication Ability. <i>Jom</i> , 2021, 73, 1684-1695.	1.9	4
556	A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment. <i>Annals of Palliative Medicine</i> , 2021, 10, 4777-4798.	1.2	9
557	Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of Tj ETQq1 1 0.784314 rgBT /Overlooked). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 42, 5-18.	0.5	2
558	Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. <i>Nature Reviews Microbiology</i> , 2021, 19, 425-441.	28.6	202
559	Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir. <i>Antiviral Research</i> , 2021, 188, 105033.	4.1	32
560	Coronavirus Disease 2019: An Overview of the Complications and Management. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 42, 1-28.		1
561	Year in Review 2020: Noteworthy Literature in Cardiothoracic Critical Care. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2021, 25, 128-137.	1.0	2
562	Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-19 Pandemic in Germany—An Ethical Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5685.	2.6	1
563	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- $\beta$ -1a and hydroxychloroquine in hospitalized patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1826-1837.	6.0	77
564	Therapeutic approaches to coronavirus infection according to "One Health" concept. <i>Research in Veterinary Science</i> , 2021, 136, 81-88.	1.9	1
565	A Mini Review on Discovery and Synthesis of Remdesivir as an Effective and Promising Drug against COVID-19. <i>Russian Journal of Bioorganic Chemistry</i> , 2021, 47, 609-621.	1.0	8
566	Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4861-4867.	2.4	7
567	Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. <i>Frontiers in Pharmacology</i> , 2021, 12, 660710.	3.5	15
568	Contribution of Syndecans to the Cellular Entry of SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5336.	4.1	35
569	Profiling Ribonucleotide and Deoxyribonucleotide Pools Perturbed by Remdesivir in Human Bronchial Epithelial Cells. <i>Frontiers in Pharmacology</i> , 2021, 12, 647280.	3.5	2
570	Using Remdesivir and Dexamethasone for Treatment of SARS-CoV-2 Shortens the patient's stay in the Hospital. <i>Asian Journal of Pharmaceutical Research</i> , 2021, , 138-140.	1.6	7
571	Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 1123-1143.	2.4	8



#	ARTICLE	IF	CITATIONS
572	Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy. <i>Current Medicinal Chemistry</i> , 2022, 29, 635-665.	2.4	11
573	Development of a New Reverse Genetics System for Ebola Virus. <i>MSphere</i> , 2021, 6, .	2.9	8
574	New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection. <i>Pharmaceuticals</i> , 2021, 14, 503.	3.8	6
575	Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1171, 122641.	2.3	16
576	Current Strategies of Antiviral Drug Discovery for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671263.	3.5	75
577	Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111330.	5.6	33
578	Quantum mechanical studies of the adsorption of Remdesivir, as an effective drug for treatment of COVID-19, on the surface of pristine, COOH-functionalized and S-, Si- and Al- doped carbon nanotubes. <i>Physica E: Low-Dimensional Systems and Nanostructures</i> , 2021, 129, 114668.	2.7	13
579	Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions. <i>Current Medicinal Chemistry</i> , 2021, 28, 3173-3192.	2.4	5
580	Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections. <i>Journal of Infection and Public Health</i> , 2021, 14, 655-660.	4.1	12
581	Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned. <i>Viruses</i> , 2021, 13, 963.	3.3	11
582	Current Overviews on COVID-19 Management Strategies. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, .	1.6	9
583	Drug combination therapy for emerging viral diseases. <i>Drug Discovery Today</i> , 2021, 26, 2367-2376.	6.4	65
584	Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response. <i>Science Advances</i> , 2021, 7, .	10.3	47
585	Hybrid physiologically based pharmacokinetic model for remdesivir: Application to SARS-CoV-2. <i>Clinical and Translational Science</i> , 2021, 14, 1082-1091.	3.1	6
586	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. <i>Pharmaceuticals</i> , 2021, 14, 520.	3.8	24
588	Modeling within-Host SARS-CoV-2 Infection Dynamics and Potential Treatments. <i>Viruses</i> , 2021, 13, 1141.	3.3	48
589	Mechanism of Inhibition of the Reproduction of SARS-CoV-2 and Ebola Viruses by Remdesivir. <i>Biochemistry</i> , 2021, 60, 1869-1875.	2.5	12
590	SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis – An updated review. <i>International Immunopharmacology</i> , 2021, 95, 107493.	3.8	27

#	ARTICLE	IF	CITATIONS
591	Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herbâ€“drug interactions in antiviral therapy. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1072-1081.	6.1	15
592	Carboxylesterase inhibitors from clinically available medicines and their impact on drug metabolism. <i>Chemico-Biological Interactions</i> , 2021, 345, 109566.	4.0	17
593	Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An inÂvitro and inÂvivo DMPK assessment. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1607-1616.	12.0	39
594	Enhanced Oral Absorption of Icaritin by Using Mixed Polymeric Micelles Prepared with a Creative Acid-Base Shift Method. <i>Molecules</i> , 2021, 26, 3450.	3.8	12
595	A Review on Analytical Strategies for the Assessment of Recently Approved Direct Acting Antiviral Drugs. <i>Critical Reviews in Analytical Chemistry</i> , 2021, , 1-23.	3.5	5
596	Therapeutic approaches to tackle COVID-19: An overview. <i>Indian Journal of Pharmacy and Pharmacology</i> , 2021, 8, 121-135.	0.2	0
597	Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19. <i>Current Medicinal Chemistry</i> , 2021, 28, 3803-3824.	2.4	8
598	Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer. <i>Biomedicines</i> , 2021, 9, 689.	3.2	74
599	The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 211-229.	4.4	10
600	Minireview: Remdesivir, A Prominent Nucleotide/Nucleoside Antiviral Drug. <i>Polycyclic Aromatic Compounds</i> , 0, , 1-8.	2.6	1
601	Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 4959-4984.	6.7	26
602	Photoredox-Catalyzed Stereoselective Synthesis of <i>C</i> -Nucleoside Analogues from Glycosyl Bromides and Heteroarenes. <i>ACS Catalysis</i> , 2021, 11, 9397-9406.	11.2	35
603	Development of ciclesonide analogues that block SARS-CoV-2 RNA replication. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 43, 128052.	2.2	2
604	Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 5811-5820.	3.7	18
605	Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 232-247.	2.4	1
606	Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19). <i>Carbohydrate Research</i> , 2021, 505, 108326.	2.3	48
607	Recent developments and opportunities in fighting COVID-19. <i>Coronaviruses</i> , 2021, 2, .	0.3	0
608	Pharmacological Treatment for the Management of COVID 19: A Narrative Review. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 614-621.	0.4	3

#	ARTICLE	IF	CITATIONS
609	Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 50.	2.5	22
610	Contemporary narrative review of treatment options for COVID-19. <i>Respirology</i> , 2021, 26, 745-767.	2.3	12
611	Remdesivir Inhibits Tubulointerstitial Fibrosis in Obstructed Kidneys. <i>Frontiers in Pharmacology</i> , 2021, 12, 626510.	3.5	11
612	Combining SARS-CoV-2 Proofreading Exonuclease and RNA-Dependent RNA Polymerase Inhibitors as a Strategy to Combat COVID-19: A High-Throughput in silico Screening. <i>Frontiers in Microbiology</i> , 2021, 12, 647693.	3.5	43
614	Novel Coronavirus Disease (COVID-19): An extensive study on evolution, global health, drug targets and vaccines. <i>International Journal of Clinical Virology</i> , 2021, 5, 054-069.	0.2	2
615	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. <i>Biochemical Journal</i> , 2021, 478, 2405-2423.	3.7	46
616	Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indication From Molecular Modeling and Simulations. <i>Frontiers in Pharmacology</i> , 2021, 12, 710778.	3.5	33
618	Evolution of the Synthesis of Remdesivir. Classical Approaches and Most Recent Advances. <i>ACS Omega</i> , 2021, 6, 19356-19363.	3.5	9
619	An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). <i>Expert Opinion on Drug Discovery</i> , 2021, , 1-10.	5.0	16
621	Comparing antiviral strategies against COVID-19 via multiscale within-host modelling. <i>Royal Society Open Science</i> , 2021, 8, 210082.	2.4	17
622	Remdesivir for the treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD014962.	2.8	90
623	Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. <i>Epilepsy Research</i> , 2021, 174, 106675.	1.6	18
624	Drug-Induced Liver Disturbance During the Treatment of COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 719308.	3.5	15
625	Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0060221.	3.2	37
626	Remdesivir interactions with sulphobutylether- $\beta$ -cyclodextrins: A case study using selected substitution patterns. <i>Journal of Molecular Liquids</i> , 2022, 346, 117157.	4.9	9
627	Topological analysis of para-line graph of Remdesivir used in the prevention of corona virus. <i>International Journal of Quantum Chemistry</i> , 2021, 121, e26778.	2.0	13
628	Theory and reality of antivirals against SARS-CoV-2. <i>World Journal of Clinical Cases</i> , 2021, 9, 6663-6673.	0.8	1
629	Development of a Scalable Lanthanide Halide/Quaternary Ammonium Salt System for the Nucleophilic Addition of Grignard Reagents to Carbonyl Groups and Application to the Synthesis of a Remdesivir Intermediate. <i>Organic Process Research and Development</i> , 2022, 26, 754-763.	2.7	5

#	ARTICLE	IF	CITATIONS
630	Remdesivir inhibits the polymerases of the novel filoviruses Lloviu and Bombali virus. <i>Antiviral Research</i> , 2021, 192, 105120.	4.1	8
631	Protective Effect of Remdesivir Against Pulmonary Fibrosis in Mice. <i>Frontiers in Pharmacology</i> , 2021, 12, 692346.	3.5	4
632	Remdesivir for the treatment of Covid-19: the value of biochemical studies. <i>Current Opinion in Virology</i> , 2021, 49, 81-85.	5.4	17
633	The impact of high-resolution structural data on stemming the COVID-19 pandemic. <i>Current Opinion in Virology</i> , 2021, 49, 127-138.	5.4	2
634	Heterocyclic compounds as antiviral drugs: Synthesis, structure–activity relationship and traditional applications. <i>Journal of Heterocyclic Chemistry</i> , 2021, 58, 2226-2260.	2.6	15
635	Anti-SARS-CoV-2 Repurposing Drug Database: Clinical Pharmacology Considerations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 973-982.	2.5	7
636	Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients. <i>Pharmaceutics</i> , 2021, 13, 1299.	4.5	3
637	Combating the progression of novel coronavirus SARS-CoV-2 infectious Disease: Current state and future prospects in molecular diagnostic and drug discovery. <i>Current Molecular Medicine</i> , 2021, 21, .	1.3	6
638	Tailor-made amino acids in the design of small-molecule blockbuster drugs. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113448.	5.5	31
639	What is the role of remdesivir in patients with COVID-19?. <i>Current Opinion in Critical Care</i> , 2021, 27, 487-492.	3.2	16
640	Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 11787-11808.	3.5	4
641	A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients. <i>Viruses</i> , 2021, 13, 1706.	3.3	9
643	Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 3784.	2.4	12
644	Topological Study of Line Graph of Remdesivir Compound Used in the Treatment of Corona Virus. <i>Polycyclic Aromatic Compounds</i> , 0, , 1-17.	2.6	8
645	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221.	9.1	233
646	Low-Valent Calix[4]arene Glycoconjugates Based on Hydroxamic Acid Bearing Linkers as Potent Inhibitors in a Model of Ebola Virus Cis-Infection and HCMV-gB-Recombinant Glycoprotein Interaction with MDDC Cells by Blocking DC-SIGN. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14332-14343.	6.4	5
647	Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0111721.	3.2	22
649	Potential drug development and therapeutic approaches for clinical intervention in COVID-19. <i>Bioorganic Chemistry</i> , 2021, 114, 105016.	4.1	11

#	ARTICLE	IF	CITATIONS
650	Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. <i>Scientific Reports</i> , 2021, 11, 19458.	3.3	9
651	Nanoparticles as an effective drug delivery system in COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112162.	5.6	22
652	Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 46, 116364.	3.0	21
654	Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation. <i>Molecules and Cells</i> , 2021, , .	2.6	3
655	In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease. <i>Biochemistry and Biophysics Reports</i> , 2021, 27, 101032.	1.3	19
656	Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0115521.	3.2	43
657	Bioactive Molecules Derived from Snake Venoms with Therapeutic Potential for the Treatment of Thrombo-Cardiovascular Disorders Associated with COVID-19. <i>Protein Journal</i> , 2021, 40, 799-841.	1.6	9
658	Discovery of potential SARS-CoV 3CL protease inhibitors from approved antiviral drugs using: virtual screening, molecular docking, pharmacophore mapping evaluation and dynamics simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-18.	3.5	6
659	The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. <i>Animal Diseases</i> , 2021, 1, 15.	1.4	4
661	“Bucket brigade” using lysine residues in RNA-dependent RNA polymerase of SARS-CoV-2. <i>Biophysical Journal</i> , 2021, 120, 3615-3627.	0.5	7
662	Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	1.8	5
663	Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro. <i>Pharmaceutics</i> , 2021, 13, 1400.	4.5	35
664	Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation. <i>Molecules and Cells</i> , 2021, 44, 688-695.	2.6	11
665	Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. <i>Antiviral Research</i> , 2021, 194, 105161.	4.1	6
666	Little in vitro effect of remdesivir on mitochondrial respiration and monoamine oxidase activity in isolated mitochondria. <i>Toxicology Letters</i> , 2021, 350, 143-151.	0.8	6
667	COVID-19 in Children. <i>Pediatric Clinics of North America</i> , 2021, 68, 961-976.	1.8	21
668	A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112228.	5.6	20
669	Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction. <i>European Journal of Medicinal Chemistry</i> , 2021, 223, 113654.	5.5	10

#	ARTICLE	IF	CITATIONS
670	COVID-19, cytokines, inflammation, and spices: How are they related?. Life Sciences, 2021, 284, 119201.	4.3	68
671	A computational overview on phylogenetic characterization, pathogenic mutations, and drug targets for Ebola virus disease. Current Opinion in Pharmacology, 2021, 61, 28-35.	3.5	0
672	Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus. European Journal of Medicinal Chemistry, 2021, 226, 113862.	5.5	8
673	Design, synthesis and evaluation of 2- <sup>2</sup> -acetylene-7-deaza-adenosine phosphoamidate derivatives as anti-EV71 and anti-EV-D68 agents. European Journal of Medicinal Chemistry, 2021, 226, 113852.	5.5	3
674	Drugs for the Treatment of COVID-19. , 2021, , 193-204.		0
675	Synthesis and biological activity of aza and deaza analogues of purine nucleosides. Russian Chemical Reviews, 2021, 90, 1454-1491.	6.5	11
676	Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis. Molecules, 2021, 26, 427.	3.8	13
677	The COVID-19 puzzle: a global nightmare. Environment, Development and Sustainability, 2021, 23, 12710-12737.	5.0	11
678	SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. Membranes, 2021, 11, 64.	3.0	0
679	Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery. Computational and Structural Biotechnology Journal, 2021, 19, 4684-4701.	4.1	27
680	Immunological mechanisms associated with clinical features of Ebola virus disease and its control and prevention. , 2021, , 159-183.		0
681	The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. International Journal of Environmental Research and Public Health, 2021, 18, 955.	2.6	6
682	Catalytic Enantioselective Synthesis of Aryl Methyl Organophosphorus Compounds. Journal of Organic Chemistry, 2021, 86, 2000-2011.	3.2	11
683	Recent advances made in the synthesis of small drug molecules for clinical applications: An insight. Current Research in Green and Sustainable Chemistry, 2021, 4, 100097.	5.6	14
684	Green and sensitive spectrofluorimetric determination of Remdesivir, an FDA approved SARS-CoV-2 candidate antiviral; application in pharmaceutical dosage forms and spiked human plasma. Analytical Methods, 2021, 13, 2596-2602.	2.7	23
685	Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic. Pharmacology, 2021, 106, 462-468.	2.2	16
686	Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications. Environmental Science and Pollution Research, 2021, 28, 40431-40444.	5.3	25
687	Antiviral Activity of 7-Substituted 7-Deazapurine Ribonucleosides, Monophosphate Prodrugs, and Triphosphates against Emerging RNA Viruses. ACS Infectious Diseases, 2021, 7, 471-478.	3.8	22

#	ARTICLE	IF	CITATIONS
689	Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19. <i>Pharmacotherapy</i> , 2020, 40, 659-671.	2.6	197
690	Assessment of Inhibition of Ebola Virus Progeny Production by Antiviral Compounds. <i>Methods in Molecular Biology</i> , 2017, 1628, 203-210.	0.9	1
691	The epidemiology and clinical information about COVID-19. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1011-1019.	2.9	424
692	How materials can beat a virus. <i>Journal of Materials Science</i> , 2020, 55, 9148-9151.	3.7	34
693	An Overview of the Crystallized Structures of the SARS-CoV-2. <i>Protein Journal</i> , 2020, 39, 600-618.	1.6	32
694	Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. <i>Protein Journal</i> , 2020, 39, 619-630.	1.6	15
695	COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine. <i>Virologica Sinica</i> , 2020, 35, 685-698.	3.0	18
696	Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More. <i>Archives of Medical Research</i> , 2020, 51, 585-586.	3.3	110
697	Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. <i>Bioorganic Chemistry</i> , 2020, 104, 104269.	4.1	74
698	COVID-19 therapy: What weapons do we bring into battle?. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115757.	3.0	22
699	Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase. <i>Cell</i> , 2020, 182, 417-428.e13.	28.9	672
700	Chemistry and Biology of SARS-CoV-2. <i>CheM</i> , 2020, 6, 1283-1295.	11.7	98
701	ACTIVating Resources for the COVID-19 Pandemic: In-Vivo Models for Vaccines and Therapeutics. <i>Cell Host and Microbe</i> , 2020, 28, 646-659.	11.0	36
702	Review of trials currently testing treatment and prevention of COVID-19. <i>Clinical Microbiology and Infection</i> , 2020, 26, 988-998.	6.0	83
703	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. <i>Drug Resistance Updates</i> , 2020, 53, 100721.	14.4	80
704	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 641-648.	3.6	142
705	Bioactive pyrrole-based compounds with target selectivity. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112783.	5.5	121
706	Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 1333-1352.	2.7	21

#	ARTICLE	IF	CITATIONS
707	COVID-19 in clinical practice: A narrative synthesis. <i>MÃ©decine Et Maladies Infectieuses</i> , 2020, 50, 639-647.	5.0	2
708	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. , 0, .		1
709	Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. <i>Bioscience Reports</i> , 2020, 40, .	2.4	129
710	Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission. <i>Clinical Science</i> , 2020, 134, 2137-2160.	4.3	68
711	Intensive Care Unitâ€™Like Care of Nonhuman Primates with Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , 2021, 224, 632-642.	4.0	3
712	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drugâ€™Drug Interactions. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 360-368.	2.0	48
745	Conformational flexibility in amidophosphoesters: a CSD analysis completed with two new crystal structures of (C<sub>6</sub>H<sub>5</sub>O)<sub>2</sub>P(O) [X] [X] = NHC<sub>7</sub>H<sub>13</sub> and N(CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>]. <i>Acta Crystallographica Section C, Structural Chemistry</i> , 2020, 76, 104-116.	0.5	6
746	A quick look at the latest developments in the COVID-19 pandemic. <i>Journal of International Medical Research</i> , 2020, 48, 030006052094380.	1.0	3
747	Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. <i>Trials</i> , 2020, 21, 422.	1.6	59
748	Battling COVID-19: using old weapons for a new enemy. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2020, 6, 6.	2.2	20
749	An overview on COVID-19: reality and expectation. <i>Bulletin of the National Research Centre</i> , 2020, 44, 86.	1.8	28
750	Epidemiology of CoViD-19 Pandemic: Recovery and mortality ratio around the globe. <i>Pakistan Journal of Medical Sciences</i> , 2020, 36, S79-S84.	0.6	29
751	The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro. <i>F1000Research</i> , 0, 9, 361.	1.6	5
752	Computational screening for potential drug candidates against the SARS-CoV-2 main protease. <i>F1000Research</i> , 2020, 9, 514.	1.6	12
753	Computational screening for potential drug candidates against the SARS-CoV-2 main protease. <i>F1000Research</i> , 2020, 9, 514.	1.6	10
754	Antiviral treatment of COVID-19: a clinical pharmacology narrative review. <i>Medical Journal of Indonesia</i> , 2020, 29, 332-45.	0.5	8
755	A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness. <i>PLoS Computational Biology</i> , 2020, 16, e1008451.	3.2	40
756	Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. <i>PLoS Medicine</i> , 2018, 15, e1002535.	8.4	108



#	ARTICLE	IF	CITATIONS
757	Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1461-1468.	2.3	36
758	COVID-19 therapy and prevention. <i>Discoveries</i> , 2020, 8, e113.	2.3	4
759	Emerging Therapeutic Strategies for COVID-19 Patients. <i>Discoveries</i> , 2020, 8, e105.	2.3	28
760	COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. <i>Discoveries</i> , 2020, 8, e108.	2.3	34
761	A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. <i>EMBO Molecular Medicine</i> , 2021, 13, e13105.	6.9	62
762	COVID-19: etiology, clinical picture, treatment. <i>Russian Journal of Infection and Immunity</i> , 2020, 10, 421-445.	0.7	36
763	COVID-19: therapeutic approaches description and discussion. <i>Anais Da Academia Brasileira De Ciencias</i> , 2020, 92, e20200466.	0.8	9
764	Use of remdesivir for patients with Covid-19: a review article. <i>Revista Da Associação Médica Brasileira</i> , 2020, 66, 838-841.	0.7	6
765	Medicamentos e tratamentos para a Covid-19. <i>Estudos Avancados</i> , 2020, 34, 7-27.	0.5	15
767	Standard finishing categories for high-throughput sequencing of viral genomes. <i>OIE Revue Scientifique Et Technique</i> , 2016, 35, 43-52.	1.2	4
770	Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. <i>Annals of Translational Medicine</i> , 2016, 4, 421-421.	1.7	108
772	Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>SSRN Electronic Journal</i> , 0, , .	0.4	15
773	Drug Repurposing Screens Reveal FDA Approved Drugs Active Against SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	7
774	Possible Targets and Therapies of SARS-CoV-2 Infection. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020, 20, 1900-1907.	2.4	2
775	COVID-19: Small-Molecule Clinical Trials Landscape. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1577-1580.	2.1	8
776	Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. <i>JMIR Medical Informatics</i> , 2020, 8, e21648.	2.6	9
778	On the novel coronavirus (COVID-19): a global pandemic. <i>Jurnal Teknologi Laboratorium</i> , 2020, 9, 103-114.	0.3	4
779	A Generalized Overview of SARS-CoV-2: Where Does the Current Knowledge Stand?. <i>Electronic Journal of General Medicine</i> , 2020, 17, em251.	0.7	12

#	ARTICLE	IF	CITATIONS
781	Medication for COVID-19 – an Overview of Approaches Currently Under Study. Deutsches Ärzteblatt International, 2020, 117, 213-219.	0.9	31
782	Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System. Biomedicines, 2021, 9, 11.	3.2	8
783	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. International Journal of Molecular Sciences, 2020, 21, 9775.	4.1	40
784	Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review. Viruses, 2020, 12, 1092.	3.3	34
785	A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures. Viruses, 2021, 13, 52.	3.3	14
786	Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community. Research, 2020, 2020, 6925296.	5.7	26
787	Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity. International Journal of Health Policy and Management, 2020, , .	0.9	6
788	Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2). International Journal of Occupational and Environmental Medicine, 2020, 11, 157-178.	4.2	16
789	Acute kidney injury in COVID-19; a review on current knowledge. Journal of Nephropathology, 2020, 9, e31-e31.	0.2	13
790	Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective. World Journal of Gastroenterology, 2020, 26, 7272-7286.	3.3	12
791	Remdesivir Research Progress: An Overview of the Emerging Evidence. Journal of Biomedical Research & Environmental Sciences, 2020, 1, 216-218.	0.2	2
792	COVID-19: What We Know So Far. International Journal of Clinical Research, 2020, 1, 73-108.	0.0	1
793	Repurposing current therapeutic regimens against SARS-CoV-2 (Review). Experimental and Therapeutic Medicine, 2020, 20, 1845-1855.	1.8	8
794	Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review). Experimental and Therapeutic Medicine, 2020, 21, 155.	1.8	6
795	Interim Guidelines on Antiviral Therapy for COVID-19. Infection and Chemotherapy, 2020, 52, 281.	2.3	29
796	Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series. Infection and Chemotherapy, 2020, 52, 369.	2.3	12
797	Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian Journal of Pharmacology, 2020, 52, 1.	0.7	64
798	Current status of COVID-19 pandemic; characteristics, diagnosis, prevention, and treatment. Journal of Research in Medical Sciences, 2020, 25, 101.	0.9	13

#	ARTICLE	IF	CITATIONS
799	Character of Frontier Orbitals of Antiviral Drugs: Candidate Drugs against Covid-19. Open Journal of Physical Chemistry, 2020, 10, 158-165.	0.6	3
800	Analytical methods for the determination of remdesivir as a promising antiviral candidate drug for the COVID-19 pandemic. Drug Discoveries and Therapeutics, 2020, 14, 273-281.	1.5	10
801	Combination Therapy with Remdesivir and Tocilizumab for COVID-19: Lessons for Futures Studies. Archives of Clinical Infectious Diseases, 2020, 15, .	0.2	3
802	The journey of remdesivir: from Ebola to COVID-19. Drugs in Context, 2020, 9, 1-9.	2.2	106
803	A Comprehensive Review of Severe Acute Respiratory Syndrome Coronavirus 2. Cureus, 2020, 12, e7943.	0.5	12
804	A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients. Journal of Pharmaceutical Research International, 0, , 13-25.	1.0	7
805	An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100063.	3.6	7
806	Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs. The Enzymes, 2021, 49, 315-354.	1.7	9
807	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. Advances in Experimental Medicine and Biology, 2021, 1313, 99-134.	1.6	6
808	HCV RdRp, sofosbuvir and beyond. The Enzymes, 2021, 49, 63-82.	1.7	5
809	Natural Potential Inhibitors for Covid 19 " An Insilico Approach. Research Journal of Pharmacy and Technology, 2021, , 4913-4919.	0.8	4
810	Programmable nano-reactors for stochastic sensing. Nature Communications, 2021, 12, 5811.	12.8	29
813	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. Current Molecular Medicine, 2022, 22, 621-639.	1.3	2
814	Current treatment strategies for COVID"19 (Review). Molecular Medicine Reports, 2021, 24, .	2.4	19
815	Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments. Environmental Science and Pollution Research, 2021, 28, 68071-68089.	5.3	15
816	Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19. Asian Journal of Pharmaceutical Sciences, 2021, 16, 772-783.	9.1	26
817	Drugs and liver injury: a not to be overlooked binomial in COVID-19. Journal of Chemotherapy, 2022, 34, 207-220.	1.5	3
818	Remdesivir triphosphate blocks DNA synthesis and increases exonucleolysis by the replicative mitochondrial DNA polymerase, Pol $\beta$ . Mitochondrion, 2021, 61, 147-158.	3.4	5

#	ARTICLE	IF	CITATIONS
819	Viral Hemorrhagic Fevers. , 0, , 141-150.		0
821	Ebola Hemorrhagic Fever: Recent Update On Disease Status, Current Therapies And Advances In Treatment. Journal of Pharmaceutical Technology Research and Management, 2017, 5, 217-234.	0.2	1
823	The COVID-19 Pandemic: Theories to Therapies. Advances in Infectious Diseases, 2020, 10, 16-28.	0.2	3
824	HYDROXYCHLOROQUINE IS NO MIRACLE CURE FOR COVID-19 INFECTION â€”IMAGING AND CLINICAL COURSE IN AN ELDERLY FEMALE. WiadomoÅci Lekarskie, 2020, 73, 1583-1585.	0.3	1
825	Antibacterial and Antiviral Effects of Water Catholyte, Oxidal with Methylene Blue and Colloidal Silver. , 2020, , .		0
827	COVID-19 â€” Ð° new viral infection: pathogenesis, diagnostics, treatment. Tuberculosis Lung Diseases HIV Infection, 2020, .	0.7	2
829	Coronavirus disease (COVID-19) in hepatic patients. Sohag Medical Journal (SMJ), 2020, .	0.1	0
830	Understanding COVID-19 - A Molecular Perspective. American Journal of Infectious Diseases and Microbiology, 2020, 8, 64-74.	0.2	0
832	Perspectives on COVID-19 therapies: conflicts and consensus. Research, Society and Development, 2020, 9, e85997019.	0.1	1
834	Clarifying the Use of Benzylidene Protecting Group for D-(+)-Ribono-1,4-Lactone, an Essential Building Block in the Synthesis of C-Nucleosides. Molecules, 2021, 26, 6447.	3.8	2
835	Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro. International Journal of Molecular Sciences, 2021, 22, 11739.	4.1	24
836	SARSâ€CoVâ€2â€”host proteome interactions for antiviral drug discovery. Molecular Systems Biology, 2021, 17, e10396.	7.2	53
837	Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clinical and Translational Science, 2022, 15, 501-513.	3.1	21
838	Impact of COVID-19 on Delivery of Chemotherapy in Hospitals in Spain and France. SSRN Electronic Journal, 0, , .	0.4	0
839	Some New Topological Invariants for Chemical Structures Used in the Treatment of COVID-19 Patients. Turkish Journal of Mathematics & Computer Science, 0, , 112-119.	0.9	0
841	Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. Molecular Biomedicine, 2020, 1, 16.	4.4	4
844	Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment. Journal of Biomedical Research & Environmental Sciences, 2020, 1, 431-438.	0.2	2
845	Zagreb Polynomials and Redefined Zagreb Indices for Chemical Structures Helpful in the Treatment of COVID-19. Scientific Inquiry and Review, 2021, 4, 33-40.	0.2	0

#	ARTICLE	IF	CITATIONS
846	Major drugs used in COVID-19 treatment: molecular mechanisms, validation and current progress in trials. <i>Coronaviruses</i> , 2020, 01, .	0.3	1
847	Sofosbuvir for the Treatment of COVID-19 Patients: Is It a Promising Therapeutic Medicine for the Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2?. <i>Avicenna Journal of Medical Biochemistry</i> , 2020, 8, 133-135.	0.3	0
848	Comparative therapeutic efficiency of remdesivir in COVID in a tertiary care center. <i>APIK Journal of Internal Medicine</i> , 2021, 9, 244.	0.1	0
849	Past, Present, and Future of Remdesivir: An Overview of the Antiviral in Recent Times. <i>Indian Journal of Critical Care Medicine</i> , 2020, 24, 570-574.	0.9	3
850	Bicyclic 5-6 Systems With One Bridgehead (Ring Junction) Nitrogen Atom: Two Extra Heteroatoms O:2. , 2020, , .		0
851	Treatment of Viral Hemorrhagic Fever in a Well-Resourced Environment. , 2020, , 473-479.		0
852	Synthetic Review of Remdesivir and Favipiravir. <i>Journal of Comparative Chemistry</i> , 2020, 04, 1-11.	0.2	3
853	Molecular mechanisms of drugs recommended in COVID-19 treatment. <i>Zdrowie Publiczne</i> , 2020, 130, 61-64.	0.1	0
858	Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis. <i>Pharmaceuticals</i> , 2021, 14, 1125.	3.8	4
859	COVID-19 Therapeutics and Vaccines: A Race to Save Lives. <i>Toxicological Sciences</i> , 2022, 185, 119-127.	3.1	8
860	Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524. <i>Viruses</i> , 2021, 13, 2228.	3.3	31
861	The Impact of COVID-19 on Liver Injury. <i>American Journal of the Medical Sciences</i> , 2022, 363, 94-103.	1.1	28
862	Remdesivir; molecular and functional measures of mitochondrial safety. <i>Toxicology and Applied Pharmacology</i> , 2021, 433, 115783.	2.8	17
865	COVID-19 Therapeutics: Making Sense of It All. <i>AACN Advanced Critical Care</i> , 2020, 31, 239-249.	1.1	0
867	Therapeutic agents currently employed against Covid-19: an effort to control the pandemic. <i>Turkish Journal of Biochemistry</i> , 2020, 45, 651-658.	0.5	0
868	Analysis of Structure, Mechanism of Action and Efficacy of Potential and Ideal COVID-19 Treatments. , 2020, 1, 197-208.		0
869	New insights on potential therapeutic options and vaccines for corona virus disease-2019. <i>Reviews in Medical Microbiology</i> , 2021, 32, 67-74.	0.9	0
870	Towards COVID-19 Prophylaxis: An AIDS Preclinical Research Perspective. <i>Biological and Applied Environmental Research: an Open Access Peer Reviewed Journal</i> , 2020, 5, .	0.3	0

#	ARTICLE	IF	CITATIONS
871	Effective Anti-SARS-CoV-2 RNA Dependent RNA Polymerase Drugs Based on Docking Methods: The Case of Milbemycin, Ivermectin, and Baloxavir Marboxil. <i>Avicenna Journal of Medical Biotechnology</i> , 2020, 12, 246-250.	0.3	7
872	Therapeutic strategies against COVID-19. <i>Acta Biomedica</i> , 2020, 91, e2020038.	0.3	3
873	Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review. <i>Iranian Journal of Pharmaceutical Research</i> , 2020, 19, 258-281.	0.5	1
874	A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2021, 13, 163-171.	0.6	1
875	A comparative study of HPLC and UV spectrophotometric methods for remdesivir quantification in pharmaceutical formulations. <i>Journal of Taibah University for Science</i> , 2021, 15, 507-513.	2.5	18
876	Human carboxylesterase 1A plays a predominant role in the hydrolytic activation of remdesivir in humans. <i>Chemico-Biological Interactions</i> , 2022, 351, 109744.	4.0	10
877	Molecular docking and dynamics studies on propolis sulabiroid-A as a potential inhibitor of SARS-CoV-2. <i>Journal of King Saud University - Science</i> , 2022, 34, 101707.	3.5	28
878	Molecular interactions in remdesivir-cyclodextrin systems. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 209, 114482.	2.8	13
879	Evaluation of role of remdesivir in covid-19 patients outcome: A retrospective analysis. <i>Indian Journal of Clinical Anaesthesia</i> , 2021, 8, 5-9.	0.1	0
880	The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. <i>Frontiers in Pharmacology</i> , 2021, 12, 704205.	3.5	89
881	Broad-Spectrum <i>In Vitro</i> Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524). <i>Microbiology Spectrum</i> , 2021, 9, e0153721.	3.0	19
882	Innovative Strategies for the Construction of Diverse 1 $\beta$ -Modified <i>C</i> -Nucleoside Derivatives. <i>Journal of Organic Chemistry</i> , 2021, 86, 16625-16640.	3.2	5
883	Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 14067-14083.	3.5	11
884	Current status of therapeutic approaches and vaccines for SARS-CoV-2. <i>Future Microbiology</i> , 2021, 16, 1319-1326.	2.0	2
886	Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 94-103.	2.5	13
887	The (Still Unknown) Hypothetical Protective Role of COVID-19 Therapy in Bladder Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 5473.	2.4	0
888	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). <i>Trials</i> , 2021, 22, 831.	1.6	2
889	Role of Flavonoids against COVID-19. <i>The Open Biology Journal</i> , 2021, 9, 47-55.	0.5	0

#	ARTICLE	IF	CITATIONS
890	Direct and Catalytic C-glycosylation of Arenes: Expeditious Synthesis of the Remdesivir Nucleoside**. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	13.8	11
891	Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic. <i>Antibiotics</i> , 2021, 10, 1477.	3.7	5
895	Direct and Catalytic C-glycosylation of Arenes: Expeditious Synthesis of the Remdesivir Nucleoside. <i>Angewandte Chemie</i> , 0, , .	2.0	1
896	Coronavirus disease-2019 and its current scenario – A review. <i>Clinical EHealth</i> , 2021, 4, 67-73.	7.5	4
897	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. <i>RSC Drug Discovery Series</i> , 2021, , 45-60.	0.3	0
898	Broad spectrum antiviral nucleosides – Our best hope for the future. <i>Annual Reports in Medicinal Chemistry</i> , 2021, 57, 109-132.	0.9	8
899	Treatment of critically ill COVID-19 patients: Practical guidelines. <i>Medicinski Podmladak</i> , 2021, 72, 49-64.	0.0	0
900	Chapter 4. Small-molecule and Synthetically Derived Antivirals for Ebola Virus and Other Filoviruses. <i>RSC Drug Discovery Series</i> , 2021, , 61-90.	0.3	0
901	Receptors on Primary Phagocytes as Therapeutic Targets Against Highly Pathogenic Emerging Viruses. <i>RSC Drug Discovery Series</i> , 2021, , 256-279.	0.3	0
902	Synthesis and Anti-dengue Virus Activity of 5-Ethynylimidazole-4-carboxamide (EICA) Nucleotide Prodrugs. <i>Chemical and Pharmaceutical Bulletin</i> , 2022, 70, 220-225.	1.3	3
903	Anno 2021: Which antivirals for the coming decade?. <i>Annual Reports in Medicinal Chemistry</i> , 2021, 57, 49-107.	0.9	4
904	Remdesivir: Investigational Antiviral Drug with Activity Against Ebola and Other Emerging and Neglected Viruses. <i>RSC Drug Discovery Series</i> , 2021, , 166-184.	0.3	0
905	Certain biochemical aspects of coronavirus infection COVID-19. <i>Bulletin of Taras Shevchenko National University of Kyiv Series Biology</i> , 2021, 86, 17-22.	0.0	0
906	On Reverse Valency Based Topological Indices of Metal-Organic Framework. <i>Polycyclic Aromatic Compounds</i> , 2023, 43, 860-873.	2.6	3
908	Activation of the SARS-CoV-2 NSP14 3'â€²â€²5'â€² exoribonuclease by NSP10 and response to antiviral inhibitors. <i>Journal of Biological Chemistry</i> , 2022, 298, 101518.	3.4	25
909	Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection. <i>IScience</i> , 2022, 25, 103684.	4.1	3
910	RdRp inhibitors and COVID-19: Is molnupiravir a good option?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112517.	5.6	49
911	Compassionate Drug Use – Time Arising for a New Law in Bulgaria in the Era of COVID-19. <i>Folia Medica</i> , 2020, 62, 592-596.	0.5	2

#	ARTICLE	IF	CITATIONS
912	Remdesivir Research Progress: An Overview of the Emerging Evidence. <i>Health Sciences</i> , 0, 2, .	0.2	0
913	Molecular docking analysis of HER-2 inhibitor from the ZINC database as anticancer agent. <i>Bioinformatics</i> , 2020, 16, 878-881.	0.5	1
915	A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2. <i>Archiv Der Pharmazie</i> , 2022, 355, e2100382.	4.1	4
916	Predicting spike protein NTD mutations of SARS-CoV-2 causing immune evasion by molecular dynamics simulations. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 3410-3419.	2.8	2
917	Hyperpolarization study on remdesivir with its biological reaction monitoring via signal amplification by reversible exchange. <i>RSC Advances</i> , 2022, 12, 4377-4381.	3.6	3
919	Molecular dynamics simulations and MM-GBSA reveal novel guanosine derivatives against SARS-CoV-2 RNA dependent RNA polymerase. <i>RSC Advances</i> , 2022, 12, 2741-2750.	3.6	10
920	Total synthesis of remdesivir. <i>Tetrahedron Letters</i> , 2022, 88, 153590.	1.4	6
921	Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development. <i>Frontiers in Chemistry</i> , 2021, 9, 819165.	3.6	51
922	Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir. <i>Journal of Biological Chemistry</i> , 2022, 298, 101529.	3.4	25
923	Grignard Reagents as Niche Bases in the Synthesis of Pharmaceutically Relevant Molecules. <i>ChemistrySelect</i> , 2022, 7, .	1.5	3
924	Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2. <i>Antiviral Research</i> , 2022, 198, 105246.	4.1	2
925	Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model. <i>MBio</i> , 2022, 13, e0304421.	4.1	17
926	Environmental impact of the reported chromatographic methods for the determination of the first FDA-Approved therapy for COVID-19 Patients, Remdesivir: A comparative study. <i>Microchemical Journal</i> , 2022, 176, 107242.	4.5	22
927	A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA-dependent RNA polymerase of wild-type and Delta subvariant AY.4 of SARS-CoV-2. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 807-818.	2.6	24
928	Inhibition of SARS-Cov-2 proteases by medicinal plant bioactive constituents: Molecular docking simulation. <i>IOP Conference Series: Earth and Environmental Science</i> , 2022, 976, 012054.	0.3	0
929	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment. <i>Medicina (Lithuania)</i> , 2022, 58, 261.	2.0	3
931	Larvicidal activity against <i>Aedes aegypti</i> and molecular docking studies of compounds extracted from the endophytic fungus <i>Aspergillus</i> sp. isolated from <i>Bertholletia excelsa</i> Humn. & Bonpl. <i>Biotechnology Letters</i> , 2022, 44, 439-459.	2.2	12
933	Recombinant Llovium virus as a tool to study viral replication and host responses. <i>PLoS Pathogens</i> , 2022, 18, e1010268.	4.7	11



#	ARTICLE	IF	CITATIONS
934	Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors. <i>Science Translational Medicine</i> , 2022, 14, eabi5229.	12.4	22
935	A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV. <i>Frontiers in Medicine</i> , 2021, 8, 628370.	2.6	35
936	Chemical Synthesis of the Anti-€COVID-19 Drug Remdesivir. <i>Current Protocols</i> , 2021, 1, e303.	2.9	4
937	Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2022, 14, eabl828.	12.4	30
938	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. <i>MBio</i> , 2021, 12, e0334721.	4.1	45
939	COVID-19 in Low- and Middle-Income Countries (LMICs): A Narrative Review from Prevention to Vaccination Strategy. <i>Vaccines</i> , 2021, 9, 1477.	4.4	25
940	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
941	Remdesivir: Mechanism of Metabolic Conversion from Prodrug to Drug. <i>Current Drug Metabolism</i> , 2022, 23, 73-81.	1.2	1
943	Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. <i>Antiviral Therapy</i> , 2022, 27, 135965352210827.	1.0	10
945	Efficacy of repurposed antiviral drugs: Lessons from COVID-19. <i>Drug Discovery Today</i> , 2022, 27, 1954-1960.	6.4	24
946	Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 338-347.	2.8	16
947	Nucleosides and emerging viruses: A new story. <i>Drug Discovery Today</i> , 2022, 27, 1945-1953.	6.4	15
948	Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes. <i>Biomedicines</i> , 2022, 10, 437.	3.2	5
949	Anti-influenza Virus Activity of Methylthio-Formycin Distinct From That of T-705. <i>Frontiers in Microbiology</i> , 2022, 13, 802671.	3.5	4
950	What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?. <i>Frontiers in Microbiology</i> , 2022, 13, 843587.	3.5	1
951	Nanomedicines Targeting Respiratory Injuries for Pulmonary Disease Management. <i>Advanced Functional Materials</i> , 2022, 32, .	14.9	9
953	Stopping pandemics before they start: Lessons learned from SARS-CoV-2. <i>Science</i> , 2022, 375, 1133-1139.	12.6	58
954	Options in the Treatment of Subacute Sclerosing Panencephalitis: Implications for Low Resource Areas. <i>Current Treatment Options in Neurology</i> , 2022, 24, 99-110.	1.8	5

#	ARTICLE	IF	CITATIONS
955	Therapeutic Strategies against Ebola Virus Infection. <i>Viruses</i> , 2022, 14, 579.	3.3	16
956	Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine. <i>Chemistry</i> , 2022, 4, 216-258.	2.2	4
958	Phosphoramidate Prodrugs Continue to Deliver: The Journey of Remdesivir (GS-5734) from the Liver to Peripheral Blood Mononuclear Cells. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 520-523.	2.8	1
960	A Helquat-like Compound as a Potent Inhibitor of Flaviviral and Coronaviral Polymerases. <i>Molecules</i> , 2022, 27, 1894.	3.8	3
961	Synthesis of diaryl phosphates using orthophosphoric acid as a phosphorus source. <i>Tetrahedron Letters</i> , 2022, 96, 153726.	1.4	0
962	Continuous-Flow Synthesis of the Nucleobase Unit of Remdesivir. <i>Engineering</i> , 2023, 21, 92-100.	6.7	3
963	The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010220.	3.0	11
965	Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study. <i>Scientific Reports</i> , 2022, 12, 5323.	3.3	7
966	Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants. <i>Pharmaceuticals</i> , 2022, 15, 445.	3.8	7
967	Development and validation of an LC-MS/MS method for simultaneous determination of remdesivir and its hydrolyzed metabolite and nucleoside, and its application in a pharmacokinetic study of normal and diabetic nephropathy mice. <i>Biomedical Chromatography</i> , 2022, 36, e5380.	1.7	1
968	Identification of novel Ebola virus inhibitors using biologically contained virus. <i>Antiviral Research</i> , 2022, 200, 105294.	4.1	5
969	Drug repositioning: Progress and challenges in drug discovery for various diseases. <i>European Journal of Medicinal Chemistry</i> , 2022, 234, 114239.	5.5	42
970	Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2. <i>Antiviral Research</i> , 2022, 200, 105278.	4.1	5
971	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. <i>Pharmacological Research</i> , 2022, 179, 106201.	7.1	23
972	The discovery and development of novel treatment strategies for filoviruses. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 139-149.	5.0	9
973	A Bibliometric Analysis of Remdesivir: A COVID-19 Vaccine. , 2021, 58, 23-60.		0
975	The atomic portrait of SARS-CoV-2 as captured by cryo-electron microscopy. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 25-34.	3.6	6
976	Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies, benefits, and challenges. <i>Journal of Medical Virology</i> , 2022, 94, 1373-1390.	5.0	35

#	ARTICLE	IF	CITATIONS
977	Recapitulating Trafficking of Nucleosides Into the Active Site of Polymerases of RNA Viruses: The Challenge and the Prize. <i>Frontiers in Medical Technology</i> , 2021, 3, 705875.	2.5	0
978	Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 8141-8158.	6.7	12
979	Drug repurposing strategies and key challenges for COVID-19 management. <i>Journal of Drug Targeting</i> , 2022, 30, 413-429.	4.4	13
980	Nanoscience versus Viruses: The SARS-CoV-2 Case. <i>Advanced Functional Materials</i> , 2022, 32, 2107826.	14.9	8
981	Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. <i>Pneumonia (Nathan Qld)</i> , 2021, 13, 14.	6.1	67
982	An <i>in vitro</i> study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. <i>Human and Experimental Toxicology</i> , 2022, 41, 096032712210892.	2.2	5
983	Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA Polymerase. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 2456-2465.	5.4	7
985	Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: A case-control study. <i>Journal of Medical Virology</i> , 2022, 94, 3653-3660.	5.0	7
986	Clinical Signs, Laboratory Diagnosis and Treatments Involved in Corona Viruses-19. <i>Al Mustansiriyah Journal of Pharmaceutical Sciences</i> , 2022, 21, 10-15.	0.6	2
987	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment. <i>Process Biochemistry</i> , 2022, 118, 154-170.	3.7	4
988	Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease. <i>JCI Insight</i> , 2022, 7, .	5.0	18
989	Mechanism of reaction of RNA-dependent RNA polymerase from SARS-CoV-2. <i>Chem Catalysis</i> , 2022, 2, 1084-1099.	6.1	20
990	Molecular docking-assisted investigation of Pd(II) complexes carrying $\alpha$ -pinic-type pyridine-thioether ligand as potential drug candidates against COVID-19. <i>Computers in Biology and Medicine</i> , 2022, 145, 105512.	7.0	3
997	Amphiphilic anti-SARS-CoV-2 drug remdesivir incorporates into the lipid bilayer and nerve terminal membranes influencing excitatory and inhibitory neurotransmission. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2022, 1864, 183945.	2.6	5
1000	A narrative review of antiviral drugs used for COVID-19 pharmacotherapy. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2021, 13, 163.	0.6	3
1001	Clinical update on the use of mesenchymal stem cells in COVID-19.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 12195-12205.	0.0	1
1002	Current strategies and future perspectives in COVID-19 therapy. , 2022, , 169-227.		0
1003	Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates. <i>Molecules</i> , 2022, 27, 2723.	3.8	29

#	ARTICLE	IF	CITATIONS
1004	Inhibitors of SARS-CoV-2 PLpro. <i>Frontiers in Chemistry</i> , 2022, 10, 876212.	3.6	38
1005	Overview of Drug Therapy of COVID-19 with Safety and the Potential Clinical Benefits. <i>Current Drug Therapy</i> , 2022, 17, .	0.3	0
1006	A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses. <i>Viruses</i> , 2022, 14, 928.	3.3	20
1007	Molecular docking assisted exploration on solubilization of poorly soluble drug remdesivir in sulfolbutyl ether-tyclocloextrin. <i>AAPS Open</i> , 2022, 8, 9.	1.3	3
1008	Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic. <i>Osong Public Health and Research Perspectives</i> , 2022, 13, 84-100.	1.9	0
1009	Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2023, 34, 429-444.	1.3	4
1010	Treatment of COVID-19 Patients Using Some New Topological Indices. <i>Journal of Chemistry</i> , 2022, 2022, 1-10.	1.9	2
1011	Mechanisms of phosphatidylserine influence on viral production: A computational model of Ebola virus matrix protein assembly. <i>Journal of Biological Chemistry</i> , 2022, 298, 102025.	3.4	4
1012	Artificial Neural Network-Based Study Predicts GS-441524 as a Potential Inhibitor of SARS-CoV-2 Activator Protein Furin: a Polypharmacology Approach. <i>Applied Biochemistry and Biotechnology</i> , 2022, 194, 4511-4529.	2.9	6
1013	Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals. <i>Arab Journal of Gastroenterology</i> , 2022, 23, 165-171.	0.9	9
1014	Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor. <i>Medicinal Chemistry Research</i> , 2022, 31, 1147-1153.	2.4	12
1015	Remdesivir efficacy against yellow fever in a hamster model. <i>Antiviral Research</i> , 2022, 203, 105331.	4.1	4
1016	Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0022222.	3.2	39
1017	Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. <i>Science Translational Medicine</i> , 2022, 14, eabo0718.	12.4	108
1018	VIRTUAL SCREENING AND MOLECULAR DOCKING ANALYSIS ON THREE SARS-COV-2 DRUG TARGETS BY MULTIPLE COMPUTATIONAL APPROACH. <i>Ankara Universitesi Eczacilik Fakultesi Dergisi</i> , 0, , .	0.1	1
1020	Repurposing of berbamine hydrochloride to inhibit Ebola virus by targeting viral glycoprotein. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 4378-4389.	12.0	5
1021	Carbohydrate-based drugs launched during 2000~2021. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3783-3821.	12.0	68
1022	Synthesis of Immucillins BCX1777 and BCX4430 from a Common Precursor. <i>European Journal of Organic Chemistry</i> , 0, , .	2.4	1

#	ARTICLE	IF	CITATIONS
1023	Drivers for the behavioural receptiveness and non-receptiveness of farmers towards organic cultivation system. Journal of King Saud University - Science, 2022, 34, 102107.	3.5	22
1024	Degree-Based Graph Invariants of some Chemical Structures for the Treatment of Corona Virus. Journal of Function Spaces, 2022, 2022, 1-15.	0.9	1
1025	Modeling explains prolonged SARS-CoV-2 nasal shedding relative to lung shedding in remdesivir-treated rhesus macaques. IScience, 2022, 25, 104448.	4.1	7
1026	Transcriptional Effects of Candidate COVID-19 Treatments on Cardiac Myocytes. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	0
1027	Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system. Microbial Pathogenesis, 2022, 168, 105608.	2.9	9
1028	Recent Updates on Diagnosis and Treatment of SARS-CoV-2: A Review. , 2021, 1, 1-8.		0
1029	FDA Coronavirus Treatment Acceleration Program: approved drugs and those in clinical trials. , 2022, , 249-264.		2
1030	Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds. Viruses, 2022, 14, 1186.	3.3	4
1031	Temperature-Based Topological Indices and QSPR Analysis of COVID-19 Drugs. Polycyclic Aromatic Compounds, 2023, 43, 4148-4169.	2.6	4
1032	In-depth investigation of the Silymarin effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 and ledipasvir in rat plasma using LC-MS. Biomedical Chromatography, 0, , .	1.7	0
1033	A Comprehensive Review on Journey of Pyrrole Scaffold Against Multiple Therapeutic Targets. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 3291-3303.	1.7	10
1034	Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity. Viruses, 2022, 14, 1345.	3.3	19
1035	Drug-Membrane Interactions: Effects of Virus-Specific RNA-Dependent RNA Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers. Biochemistry, 2022, 61, 1392-1403.	2.5	5
1036	Eco-friendly stability-indicating HPTLC micro-determination of the first FDA approved SARS-CoV-2 antiviral prodrug Remdesivir: Study of degradation kinetics and structural elucidation of the degradants using HPTLC-MS. Sustainable Chemistry and Pharmacy, 2022, 29, 100744.	3.3	9
1037	Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study. Indian Journal of Transplantation, 2022, 16, 216.	0.1	2
1038	Genomic, proteomic and metabolomic profiling of severe acute respiratory syndrome-Coronavirus-2. , 2022, , 49-76.		0
1039	Therapeutic Repurposing of Antiviral Drugs Available for COVID-19 Therapy: A Mini Review. Asian Journal of Chemistry, 2022, 34, 1993-1996.	0.3	0
1040	Partition dimension of COVID antiviral drug structures. Mathematical Biosciences and Engineering, 2022, 19, 10078-10095.	1.9	4

#	ARTICLE	IF	CITATIONS
1041	Thyroid Function During and After COVID-19 Infection: A Review. , 2022, 18, 58.		6
1042	How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. <i>Blood</i> , 2022, 140, 673-684.	1.4	20
1043	A Review: Remdesivir and Covid-19. <i>International Journal of Advanced Research in Science, Communication and Technology</i> , 0, , 501-506.	0.0	0
1044	Overview of Hydroxychloroquine and Remdesivir on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Journal of Heterocyclic Chemistry</i> , 2023, 60, 165-182.	2.6	4
1045	Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency. <i>Frontiers in Microbiology</i> , 0, 13, .	3.5	6
1046	Role of natural products towards the SARS-CoV-2: A critical review. <i>Annals of Medicine and Surgery</i> , 2022, 80, .	1.1	8
1048	Synthetic Approaches to the New Drugs Approved During 2020. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9607-9661.	6.4	18
1049	Development and validation of a paper spray mass spectrometry method for the rapid quantitation of remdesivir and its active metabolite, GS-441524, in human plasma. <i>Journal of Mass Spectrometry and Advances in the Clinical Lab</i> , 2022, 25, 27-35.	2.4	4
1050	Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8845.	2.6	9
1051	A Systematic Study on the Optimal Nucleotide Analogue Concentration and Rate Limiting Nucleotide of the SARS-CoV-2 RNA-Dependent RNA Polymerase. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8302.	4.1	4
1052	Practical and Highly Efficient Synthesis of Remdesivir from GS-441524. <i>ACS Omega</i> , 0, , .	3.5	2
1053	Valency based topological descriptors of para line graph of Remdesivir used in the prevention of Corona virus. <i>Journal of Information and Optimization Sciences</i> , 2022, 43, 821-835.	0.3	0
1054	Drugs targeting the viral enzymes of SARS-CoV-2. <i>Medical Biological Science and Engineering</i> , 2022, 5, 47-51.	0.2	0
1055	The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs. <i>Pharmaceutics</i> , 2022, 14, 1776.	4.5	8
1057	On Reverse Valency Based Topological Characterization of a Chemical Compound. <i>Journal of Mathematics</i> , 2022, 2022, 1-17.	1.0	1
1058	Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 483-505.	3.3	2
1060	Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814.	3.8	47
1061	Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	12

#	ARTICLE	IF	CITATIONS
1062	Prodrugs of Nucleoside 5'-Monophosphate Analogues: Overview of the Recent Literature Concerning their Synthesis and Applications. <i>Current Medicinal Chemistry</i> , 2022, 29, .	2.4	3
1063	TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model. <i>IScience</i> , 2022, 25, 105074.	4.1	5
1064	EBOLApred: A machine learning-based web application for predicting cell entry inhibitors of the Ebola virus. <i>Computational Biology and Chemistry</i> , 2022, 101, 107766.	2.3	4
1065	Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals. <i>Annual Reports in Medicinal Chemistry</i> , 2022, , 55-92.	0.9	0
1066	Safety and sagacious use of remdesivir: Paramount focus on contemporary perspectives. <i>Biomedical and Biotechnology Research Journal</i> , 2022, 6, 1.	0.6	0
1067	Tempol Inhibits SARS-CoV-2 Replication and Development of Lung Disease in the Syrian Hamster Model. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1068	Drug Repurposing in Biomedical Research: Benefits and Challenges. , 2022, , 27-35.		0
1069	Nanocarriers as delivery tool for COVID-19 drugs. , 2022, , 293-332.		1
1070	Remdesivir-Induced Pancreatitis in a Patient With Coronavirus Disease 2019. <i>Pancreas</i> , 2022, 51, e88-e89.	1.1	3
1071	Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 12044-12054.	6.4	7
1072	Cationic Perylene Antivirals with Aqueous Solubility for Studies In Vivo. <i>Pharmaceuticals</i> , 2022, 15, 1178.	3.8	3
1073	State-of-the-Art Molecular Dynamics Simulation Studies of RNA-Dependent RNA Polymerase of SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10358.	4.1	5
1074	Structure of the Ebola virus polymerase complex. <i>Nature</i> , 2022, 610, 394-401.	27.8	22
1075	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 0, , .	5.8	82
1076	Candidate Drugs for the Potential Treatment of Coronavirus Diseases. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 85-114.	0.2	0
1077	Discovery of small molecule antivirals targeting tick-borne encephalitis virus. <i>Annual Reports in Medicinal Chemistry</i> , 2022, , 1-54.	0.9	3
1078	Development and Validation of Novel Rapid Stability Indicating Mass Compatible UPLC Method for the Simultaneous Estimation of Assay and Related Substances of Remdesivir in Bulk and Injectable Dosage Form. <i>Asian Journal of Chemistry</i> , 2022, 34, 2826-2832.	0.3	0
1079	Clinical outcomes of remdesivir-treated COVID-19 patients in South Korea. <i>Osong Public Health and Research Perspectives</i> , 2022, 13, 370-376.	1.9	2

#	ARTICLE	IF	CITATIONS
1080	Inhibition of Viral RNA-Dependent RNA Polymerases by Nucleoside Inhibitors: An Illustration of the Unity and Diversity of Mechanisms. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12649.	4.1	4
1081	1 $\beta$ -Cyano Intermediate Enables Rapid and Stereoretentive Access to 1 $\beta$ -Modified Remdesivir Nucleosides. <i>Journal of Organic Chemistry</i> , 2022, 87, 14452-14462.	3.2	1
1082	Remdesivir does not affect mitochondrial DNA copy number or deletion mutation frequency in aged male rats: A short report. <i>PLoS ONE</i> , 2022, 17, e0271850.	2.5	2
1083	Medications for early treatment of COVID-19 in Australia. <i>Medical Journal of Australia</i> , 0, , .	1.7	0
1084	Vertex metric resolvability of COVID antiviral drug structures. <i>Journal of Intelligent and Fuzzy Systems</i> , 2022, , 1-12.	1.4	2
1086	Natural History of Marburg Virus Infection to Support Medical Countermeasure Development. <i>Viruses</i> , 2022, 14, 2291.	3.3	6
1087	An efficient triphosphate synthesis of a novel broad-spectrum antiviral nucleoside BCX4430. <i>Tetrahedron Letters</i> , 2023, 114, 154219.	1.4	2
1088	An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats. <i>Viruses</i> , 2022, 14, 2429.	3.3	13
1089	Analyzing the Impermeable Structure and Myriad of Antiviral Therapies for SARS-CoV-2. <i>Journal of the Association of Physicians of India</i> , The, 2022, 70, 80-84.	0.0	0
1090	Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells. <i>Scientific Reports</i> , 2022, 12, .	3.3	6
1091	COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, , 1-12.	0.3	0
1092	Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19). <i>Journal of Clinical Medicine</i> , 2022, 11, 6545.	2.4	4
1093	Synthetic Platforms for Characterizing and Targeting of SARS-CoV-2 Genome Capping Enzymes. <i>ACS Synthetic Biology</i> , 2022, 11, 3759-3771.	3.8	2
1094	Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
1095	6-Thioguanosine Monophosphate Prodrugs Display Enhanced Performance against Thiopurine-Resistant Leukemia and Breast Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 15165-15173.	6.4	5
1096	In vitro and in vivo effects of 3-indoleacetonitrile—A potential new broad-spectrum therapeutic agent for SARS-CoV-2 infection. <i>Antiviral Research</i> , 2022, , 105465.	4.1	0
1097	The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion. <i>Journal of Infection and Public Health</i> , 2023, 16, 42-54.	4.1	4
1098	Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy. <i>Current Opinion in Virology</i> , 2022, 57, 101279.	5.4	7



#	ARTICLE	IF	CITATIONS
1099	Antiviral Agents. , 2023, , 1583-1598.e6.		1
1100	Multiplication of defective Ebola virus in a complementary permissive cell line. Antiviral Research, 2023, 209, 105491.	4.1	0
1101	Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress. Biomedicine and Pharmacotherapy, 2023, 157, 114037.	5.6	2
1102	The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells. European Journal of Pharmaceutical Sciences, 2023, 181, 106345.	4.0	4
1103	COVID-19 signalome: Potential therapeutic interventions. Cellular Signalling, 2023, 103, 110559.	3.6	5
1104	Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals. International Journal of Peptide Research and Therapeutics, 2023, 29, .	1.9	10
1105	Antiviral Treatment of COVID-19 Pneumonia. Clinics in Chest Medicine, 2022, , .	2.1	0
1106	Identification of FDA-approved drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through computational virtual screening. Structural Chemistry, 2023, 34, 1005-1019.	2.0	3
1108	Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2. Antiviral Research, 2023, 210, 105501.	4.1	12
1109	Therapeutic challenges in COVID-19. Current Molecular Medicine, 2022, 23, .	1.3	0
1110	SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments. Vaccines, 2022, 10, 2145.	4.4	4
1111	Viral proteases as therapeutic targets. Molecular Aspects of Medicine, 2022, 88, 101159.	6.4	17
1112	Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters. Frontiers in Pharmacology, 0, 13, .	3.5	9
1113	Discovery and Chemical Development of Adafosbuvir, a Nucleoside Phosphoramidate Prodrug for the Treatment of Hepatitis C Infection. ACS Symposium Series, 0, , 95-141.	0.5	0
1114	An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight. Molecules, 2023, 28, 795.	3.8	8
1115	Modified Synthesis and Isolation of an Advanced Intermediate of Remdesivir. Current Organic Chemistry, 2023, 26, 2143-2150.	1.6	0
1116	Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine. OMICS A Journal of Integrative Biology, 2023, 27, 6-14.	2.0	2
1117	Experimental and computational snapshots of C-C bond formation in a C-nucleoside synthase. Open Biology, 2023, 13, .	3.6	3

#	ARTICLE	IF	CITATIONS
1118	A Recent Update on SARS-CoV-2 Transmission and its Variants: Transmission, Pathogenic Mechanism, and Treatment. <i>Coronaviruses</i> , 2023, 4, .	0.3	1
1119	Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19. <i>PLoS ONE</i> , 2022, 17, e0278963.	2.5	2
1120	Recent updates on the biological efficacy of approved drugs and potent synthetic compounds against SARS-CoV-2. <i>RSC Advances</i> , 2023, 13, 3677-3687.	3.6	4
1121	Currently available COVID-19 management options. , 2023, , 111-124.		0
1122	Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2. <i>Oxford Open Immunology</i> , 2023, 4, .	2.8	3
1123	Remdesivir. <i>Profiles of Drug Substances, Excipients and Related Methodology</i> , 2023, , 71-108.	8.0	6
1124	Energetic<i>vs.</i>entropic stabilization between a Remdesivir analogue and cognate ATP upon binding and insertion into the active site of SARS-CoV-2 RNA dependent RNA polymerase. <i>Physical Chemistry Chemical Physics</i> , 2023, 25, 13508-13520.	2.8	3
1125	Drug Delivery Options for Treatment of Ebola Infection. , 2023, , 161-191.		0
1127	Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2. <i>European Journal of Medicinal Chemistry</i> , 2023, 252, 115292.	5.5	6
1128	VekluryÂ®(remdesivir) formulations inhibit initial membraneâ€coupled events of SARSâ€CoVâ€2 infection due to their sulfobutyletherâ€2â€cyclodextrin content. <i>British Journal of Pharmacology</i> , 2023, 180, 2064-2084.	5.4	6
1129	Characterization of in-vivo human metabolites of the oral nucleoside anti-COVID-19 drug VV116 using UHPLC-Orbitrap-MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, 228, 115340.	2.8	4
1130	Viral target and metabolismâ€based rationale for combined use of recently authorized small molecule COVIDâ€19 medicines: Molnupiravir, nirmatrelvir, and remdesivir. <i>Fundamental and Clinical Pharmacology</i> , 2023, 37, 726-738.	1.9	5
1131	Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. <i>Heliyon</i> , 2023, 9, e13285.	3.2	4
1132	Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication. <i>Viruses</i> , 2023, 15, 452.	3.3	3
1133	How to use COVID-19 antiviral drugs in patients with chronic kidney disease. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	7
1134	Is it possible to reduce the rate of vertical transmission and improve perinatal outcomes by inclusion of remdesivir in treatment regimen of pregnant women with COVIDâ€19?. <i>BMC Pregnancy and Childbirth</i> , 2023, 23, .	2.4	3
1135	Population pharmacokinetics and exposureâ€clinical outcome relationship of remdesivir major metabolite <sc>GS</sc>â€441524 in patients with moderate and severe <sc>COVID</sc>â€19. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 513-521.	2.5	2
1136	Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients. <i>Hepatology Communications</i> , 2023, 7, e0034-e0034.	4.3	2

#	ARTICLE	IF	CITATIONS
1137	Preparation of Vinylphosphonates from Ketones Promoted by $Tf_2O$ . Journal of Organic Chemistry, 2023, 88, 2898-2907.	3.2	1
1138	Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respiratory Medicine, 2023, 11, 453-464.	10.7	35
1139	First detected geographical cluster of BoDV-1 encephalitis from same small village in two children: therapeutic considerations and epidemiological implications. Infection, 2023, 51, 1383-1398.	4.7	5
1140	Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro. Scientific Reports, 2023, 13, .	3.3	10
1141	Antiviral Peptides in Antimicrobial Surface Coatings—From Current Techniques to Potential Applications. Viruses, 2023, 15, 640.	3.3	1
1142	Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population. Molecules, 2023, 28, 2332.	3.8	6
1143	Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments. Journal of Infectious Diseases, 0, , .	4.0	5
1144	Enhanced Remdesivir Analogues to Target SARS-CoV-2. Molecules, 2023, 28, 2616.	3.8	0
1145	Modulation of gut microbiota as a potential therapy to manipulate drug-induced hepatic damage in COVID-19 patients. World Journal of Gastroenterology, 0, 29, 1708-1720.	3.3	3
1146	Reviews of drug candidates for COVID-19. , 0, 36, 219-226.		0
1147	New workflow predicts drug targets against SARS-CoV-2 via metabolic changes in infected cells. PLoS Computational Biology, 2023, 19, e1010903.	3.2	3
1148	Enantioselective electrochemical cobalt-catalyzed aryl C-H activation reactions. Science, 2023, 379, 1036-1042.	12.6	66
1149	Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome in patients with COVID-19 infection: is there a link? A systematic review and case report analysis. Journal of Neurology, 0, , .	3.6	1
1150	1-Octadecyl-2-benzyl-sn-glycerol-3-phospho-GS-441524 (V2043). Evaluation of Oral V2043 in a Mouse Model of SARS-CoV-2 Infection and Synthesis and Antiviral Evaluation of Additional Phospholipid Esters with Enhanced Anti-SARS-CoV-2 Activity. Journal of Medicinal Chemistry, 2023, 66, 5802-5819.	6.4	3
1151	Approaches to the synthesis of heterocyclic C-nucleosides. Russian Chemical Bulletin, 2023, 72, 425-481.	1.5	2
1152	Repurposed Drugs Against SARS-CoV-2 Replication in COVID-19. , 2023, , 52-71.		1
1153	Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. European Journal of Clinical Pharmacology, 2023, 79, 723-751.	1.9	7
1154	Effect of remdesivir post-exposure prophylaxis and treatment on pathogenesis of measles in rhesus macaques. Scientific Reports, 2023, 13, .	3.3	2

#	ARTICLE	IF	CITATIONS
1155	DTSEA: A network-based drug target set enrichment analysis method for drug repurposing against COVID-19. <i>Computers in Biology and Medicine</i> , 2023, 159, 106969.	7.0	6
1156	Targeting the vital non-structural proteins (NSP12, NSP7, NSP8 and NSP3) from SARS-CoV-2 and inhibition of RNA polymerase by natural bioactive compound naringenin as a promising drug candidate against COVID-19. <i>Journal of Molecular Structure</i> , 2023, 1287, 135642.	3.6	4
1157	Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections. <i>Pharmaceutical Research</i> , 2023, 40, 1015-1036.	3.5	3
1158	Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction. <i>Communications Biology</i> , 2023, 6, .	4.4	1
1159	Preparing for the next viral threat with broad-spectrum antivirals. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	5
1160	Methods in Drug Repurposing: Emphasis on COVID-19. , 2023, , 111-126.		0
1161	Multistep Synthesis of Analogues of Remdesivir: Incorporating Heterocycles at the C-1â€² Position. <i>Journal of Organic Chemistry</i> , 0, , .	3.2	0
1162	A Tale of Two Proteases: MPro and TMPRSS2 as Targets for COVID-19 Therapies. <i>Pharmaceuticals</i> , 2023, 16, 834.	3.8	0
1163	Investigation of hydrogen bonding in small nucleobases using DFT, AIM, NCI and NBO technique. <i>Computational and Theoretical Chemistry</i> , 2023, 1226, 114188.	2.5	6
1164	Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines. <i>Virology</i> , 2023, 585, 179-185.	2.4	2
1165	Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2. <i>Topics in Current Chemistry</i> , 2023, 381, .	5.8	6
1166	Clinically Evaluated COVID-19 Drugs with Therapeutic Potential for Biological Warfare Agents. <i>Microorganisms</i> , 2023, 11, 1577.	3.6	0
1168	A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance. <i>MBio</i> , 0, , .	4.1	3
1169	Paramyxoviruses: Henipaviruses. , 2023, , 1-51.		0
1170	Late remdesivir treatment initiation partially protects African green monkeys from lethal Nipah virus infection. <i>Antiviral Research</i> , 2023, , 105658.	4.1	1
1171	Two are not enough: synthetic strategies and applications of unnatural base pairs. <i>Biological Chemistry</i> , 2023, 404, 883-896.	2.5	4
1172	Synthesis of Remdesivir by Direct Lithiation of Pyrrolo[2,1â€²<i>f</i>][1,2,4]triazine Derivatives Enabled <i>C</i>-Glycosylation. <i>European Journal of Organic Chemistry</i> , 2023, 26, .	2.4	1
1174	Remdesivir Efficacy and Tolerability in Children with COVID-19-Associated Allergic Comorbidities such as Asthma, Allergic Rhinitis, and Atopic Dermatitis. <i>Children</i> , 2023, 10, 810.	1.5	4

#	ARTICLE	IF	CITATIONS
1175	Catalytic enantioselective nucleophilic desymmetrization of phosphonate esters. <i>Nature Chemistry</i> , 2023, 15, 714-721.	13.6	14
1176	Development of a novel minigenome and recombinant VSV expressing Seoul hantavirus glycoprotein-based assays to identify anti-hantavirus therapeutics. <i>Antiviral Research</i> , 2023, 214, 105619.	4.1	0
1177	Magnetic Resonance Imaging for Monitoring of Hepatic Disease Induced by Ebola Virus: a Nonhuman Primate Proof-of-Concept Study. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	0
1178	Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China. <i>European Journal of Medicinal Chemistry</i> , 2023, 257, 115503.	5.5	37
1179	<i>Trametes elegans</i> : Sources and Potential Medicinal and Food Applications. , 2023, 19, 348-353.		1
1180	Evaluation of the Antiviral Efficacy of Subcutaneous Nafamostat Formulated with Glycyrrhizic Acid against SARS-CoV-2 in a Murine Model. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9579.	4.1	0
1181	Sudan virus disease – A quick review. <i>Journal of the Formosan Medical Association</i> , 2024, 123, 16-22.	1.7	2
1182	Long-Term Vaccination and Treatment Strategies for COVID-19 Disease and Future Coronavirus Pandemics. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 27-49.	1.6	0
1183	Evaluation of safety and effectiveness of remdesivir in treating COVID-19 patients after emergency use authorization study. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
1184	Design and Application of Peptide-Mimic Phosphonium Salt Catalysts in Asymmetric Synthesis. <i>Angewandte Chemie</i> , 2023, 135, .	2.0	0
1185	Design and Application of Peptide-Mimic Phosphonium Salt Catalysts in Asymmetric Synthesis. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	13.8	2
1186	The Metallodrug BOLD-100 Is a Potent Inhibitor of SARS-CoV-2 Replication and Has Broad-Acting Antiviral Activity. <i>Biomolecules</i> , 2023, 13, 1095.	4.0	1
1187	Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524. <i>Journal of Veterinary Internal Medicine</i> , 2023, 37, 1772-1783.	1.6	8
1188	Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review. <i>Antibiotics</i> , 2023, 12, 1220.	3.7	7
1189	Infections caused by respiratory syncytial viruses - epidemiology, clinical picture, diagnosis, prevention and treatment options. <i>Cesko-Slovenska Pediatrie</i> , 2023, 78, 13-19.	0.2	0
1190	VEKLURY® (REMDESIVIR), A NUCLEOTIDE PRODRUG APPROVED FOR THE TREATMENT OF COVID-19. <i>Medicinal Chemistry Reviews</i> , 0, , 545-569.	0.1	1
1191	Nanotechnological strategies for drug delivery and treatment of COVID-19. , 2023, , 301-333.		0
1192	Quantification of GS-441524 concentration in feline plasma using high performance liquid chromatography with fluorescence detection. <i>Veterinary Quarterly</i> , 2023, 43, 1-9.	6.7	1

#	ARTICLE	IF	CITATIONS
1193	Synthesis and Characterization of Phosphate-Catecholate Chelated Nd(III), Zr(IV), and Al(III) Complexes. <i>European Journal of Inorganic Chemistry</i> , 2023, 26, .	2.0	0
1194	Conventional Understanding of SARS-CoV-2 M <sup>pro</sup> and Common Strategies for Developing Its Inhibitors. <i>ChemBioChem</i> , 2023, 24, .	2.6	0
1195	The possible techniques that used to improve the bioavailability, pharmacological activity, solubility and permeability of anti-viral drugs: Insight for COVID-19 antiviral drugs. <i>Al Mustansiriyah Journal of Pharmaceutical Sciences</i> , 2023, 23, 231-249.	0.6	0
1196	Recent Efforts in Identification of Privileged Scaffolds as Antiviral Agents. <i>Chemistry and Biodiversity</i> , 2023, 20, .	2.1	0
1197	Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 11701-11717.	6.4	3
1198	Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis. <i>Swiss Medical Weekly</i> , 2023, 153, 40095.	1.6	0
1200	Catalytic Asymmetric P <sup>H</sup> Insertion Reactions. <i>Journal of the American Chemical Society</i> , 2023, 145, 20031-20040.	13.7	1
1201	Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities. <i>Viruses</i> , 2023, 15, 1826.	3.3	1
1202	Rescue and characterization of the first West African Marburg virus 2021 from Guinea. <i>Heliyon</i> , 2023, 9, e19613.	3.2	0
1203	Phosphorus (V) Stereochemistry and Industrial Applications. , 2023, , .		0
1204	Diastereotopic groups in two new single-enantiomer structures ( <i>R</i> ) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 352 Td (<sub>2</sub>) Crystallographic Communications, 2023, 79, 769-776.	0.5	0
1205	A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19. <i>European Journal of Medicinal Chemistry</i> , 2023, 260, 115719.	5.5	4
1206	3-Halopyrazolo[1,5-a]pyrimidines as promising precursors of novel C-nucleosides. <i>Russian Chemical Bulletin</i> , 2023, 72, 1821-1836.	1.5	0
1208	Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants. <i>Clinical and Translational Science</i> , 2023, 16, 2276-2288.	3.1	1
1209	Prevention and post-exposure management of occupational exposure to Ebola virus. <i>Lancet Infectious Diseases</i> , The, 2024, 24, e93-e105.	9.1	0
1210	COVID antiviral drug structures and their edge metric dimension. <i>Molecular Physics</i> , 0, , .	1.7	2
1212	Filoviruses: Scientific Gaps and Prototype Pathogen Recommendation. <i>Journal of Infectious Diseases</i> , 2023, 228, S446-S459.	4.0	1
1213	Pharmacokinetics of GS-441524, the active metabolite of remdesivir, in patients receiving continuous renal replacement therapy: A case series. <i>Journal of Infection and Chemotherapy</i> , 2024, 30, 348-351.	1.7	0

#	ARTICLE	IF	CITATIONS
1214	Remdesivir Derivative WV116 Is a Potential Broad-Spectrum Inhibitor of Both Human and Animal Coronaviruses. <i>Viruses</i> , 2023, 15, 2295.	3.3	0
1215	Development of an EBOV MiniG plus system as an advanced tool for anti-Ebola virus drug screening. <i>Heliyon</i> , 2023, 9, e22138.	3.2	0
1216	Helix-based screening with structure prediction using artificial intelligence has potential for the rapid development of peptide inhibitors targeting class I viral fusion. <i>RSC Chemical Biology</i> , 2024, 5, 131-140.	4.1	0
1217	Drug-drug interactions between COVID-19 drug therapies and antidepressants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2023, 19, 937-950.	3.3	1
1218	Natural history of Ebola virus disease in rhesus monkeys shows viral variant emergence dynamics and tissue-specific host responses. <i>Cell Genomics</i> , 2023, , 100440.	6.5	0
1219	Expansion of Genetic Alphabets: Designer Nucleobases and Their Applications. <i>Synlett</i> , 0, , .	1.8	0
1220	Trapping a non-cognate nucleotide upon initial binding for replication fidelity control in SARS-CoV-2 RNA dependent RNA polymerase. <i>Physical Chemistry Chemical Physics</i> , 2024, 26, 1792-1808.	2.8	0
1221	Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2024, 24, 266-274.	9.1	1
1222	Remdesivir may hinder the function of Recombination Activating Gene-1 (RAG1). <i>Medical Hypotheses</i> , 2024, 182, 111228.	1.5	0
1223	Clinical efficiency and safety of riamilovir under various dosage regimens for treatment of acute respiratory viral infections in adults. <i>Terapevticheskii Arkhiv</i> , 2023, 95, 930-936.	0.8	0
1224	An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic. <i>International Journal of Molecular Sciences</i> , 2024, 25, 354.	4.1	1
1225	Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates. <i>Chemical Society Reviews</i> , 2024, 53, 2099-2210.	38.1	0
1226	Peripheral immune responses to filoviruses in a reservoir versus spillover hosts reveal transcriptional correlates of disease. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
1227	Recent Advancements in the Therapeutic Development for Marburg Virus: Updates on Clinical Trials. <i>Current Infectious Disease Reports</i> , 2024, 26, 57-67.	3.0	0
1228	Role of miRNA in Ebola diagnosis and therapeutics. , 2024, , 135-163.		0
1229	Paving new roads toward the advancement of broad-spectrum antiviral agents. <i>Journal of Medical Virology</i> , 2024, 96, .	5.0	0
1230	Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry. <i>Drugs</i> , 2024, 84, 209-217.	10.9	0
1231	New Approaches to Etiotropic Therapy of ARVI Patients with Riamilovir. <i>Antibiotiki I Khimioterapiya</i> , 2024, 68, 63-71.	0.6	0

#	ARTICLE	IF	CITATIONS
1232	A ProTide of AZT Shows Activity Against Human Papillomaviruses. <i>ChemMedChem</i> , 2024, 19, .	3.2	0
1233	In-silico study MM/GBSA binding free energy and molecular dynamics simulation of some designed remdesivir derivatives as the inhibitory potential of SARS-CoV-2 main protease. <i>Research in Pharmaceutical Sciences</i> , 2024, 19, 29-41.	1.8	0
1234	Management of viral infections: vaccines or antivirals. <i>Future Virology</i> , 2023, 18, 1031-1033.	1.8	0
1235	Shaping the future of antiviral Treatment: Spotlight on Nucleobase-Containing drugs and their revolutionary impact. <i>Bioorganic Chemistry</i> , 2024, 144, 107150.	4.1	0
1236	Assessing <i>in vitro</i> stability of remdesivir (GS-5734) and conversion to GS-441524 in feline plasma and whole blood. <i>Veterinary Quarterly</i> , 2024, 44, 1-9.	6.7	0
1237	Isolation, characterization, and circulation sphere of a filovirus in fruit bats. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2024, 121, .	7.1	0
1238	Effect of anti-COVID-19 drugs on patients with cancer. <i>European Journal of Medicinal Chemistry</i> , 2024, 268, 116214.	5.5	0
1239	Identification of CYFIP2 Arg87Cys Ligands via In Silico and In Vitro Approaches. <i>Biomedicines</i> , 2024, 12, 479.	3.2	0
1240	Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability. <i>Antimicrobial Agents and Chemotherapy</i> , 2024, 68, .	3.2	0
1242	Antiviral drug recognition and elevator-type transport motions of CNT3. <i>Nature Chemical Biology</i> , 0, , .	8.0	0
1243	New perspective of small-molecule antiviral drugs development for RNA viruses. <i>Virology</i> , 2024, 594, 110042.	2.4	0
1244	Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2024, 68, .	3.2	0
1245	Oral administration of obeldesivir protects nonhuman primates against <i>Sudan ebolavirus</i> . <i>Science</i> , 2024, 383, .	12.6	0